



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

ESPEN guideline on clinical nutrition in acute and chronic pancreatitis

Arvanitakis, Marianna; Ockenga, Johann; Bezmarevic, Mihailo; Gianotti, Luca; Krznari, Željko; Lobo, Dileep N; Löser, Christian; Madl, Christian; Meier, Remy; Phillips, Mary; Rasmussen, Henrik Højgaard; Van Hooft, Jeanin E; Bischoff, Stephan C

Published in:
Clinical Nutrition

DOI (link to publication from Publisher):
[10.1016/j.clnu.2020.01.004](https://doi.org/10.1016/j.clnu.2020.01.004)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2020

Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Arvanitakis, M., Ockenga, J., Bezmarevic, M., Gianotti, L., Krznari, Ž., Lobo, D. N., Löser, C., Madl, C., Meier, R., Phillips, M., Rasmussen, H. H., Van Hooft, J. E., & Bischoff, S. C. (2020). ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. *Clinical Nutrition*, 39(3), 612-631.
<https://doi.org/10.1016/j.clnu.2020.01.004>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -


Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Journal Pre-proof

ESPEN guideline on clinical nutrition in acute and chronic pancreatitis

Marianna Arvanitakis, Johann Ockenga, Mihailo Bezmarevic, Luca Gianotti, Željko Krznarić, Dileep N. Lobo, Christian Löser, Christian Madl, Remy Meier, Mary Phillips, Henrik Højgaard Rasmussen, Jeanin E. Van Hooft, Stephan C. Bischoff



PII: S0261-5614(20)30009-1

DOI: <https://doi.org/10.1016/j.clnu.2020.01.004>

Reference: YCLNU 4130

To appear in: *Clinical Nutrition*

Received Date: 29 December 2019

Accepted Date: 8 January 2020

Please cite this article as: Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznarić Ž, Lobo DN, Löser C, Madl C, Meier R, Phillips M, Rasmussen HH, Van Hooft JE, Bischoff SC, ESPEN guideline on clinical nutrition in acute and chronic pancreatitis, *Clinical Nutrition*, <https://doi.org/10.1016/j.clnu.2020.01.004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

1 ESPEN guideline on clinical nutrition in acute and chronic pancreatitis

2
3 Marianna Arvanitakis^a, Johann Ockenga^b, Mihailo Bezmarevic^c, Luca Gianotti^d, Željko
4 Krznarić^e, Dileep N. Lobo^f, Christian Löser^g, Christian Madl^h, Remy Meieriⁱ, Mary Phillips^k,
5 Henrik Højgaard Rasmussen^l, Jeanin E. Van Hooft^m, Stephan C. Bischoffⁿ

6
7 a Department of Gastroenterology, Erasme University Hospital ULB, Brussels, Belgium

8 b Department of Gastroenterology, Endocrinology and Clinical Nutrition, Klinikum
9 Bremen Mitte, Bremen, Germany

10 c Department of Hepatobiliary and Pancreatic Surgery, Clinic for General Surgery,
11 Military Medical Academy, University of Defense, Belgrade, Serbia

12 d School of Medicine and Surgery, University of Milano-Bicocca and Department of
13 Surgery, San Gerardo Hospital, Monza, Italy

14 e Department of Gastroenterology, Hepatology and Nutrition, Clinical Hospital Centre &
15 School of Medicine, Zagreb, Croatia.

16 f Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for
17 Health Research. (NIHR) Nottingham Biomedical Research Centre, Nottingham
18 University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre,
19 Nottingham, NG7 2UH, UK, and MRC Versus Arthritis Centre for Musculoskeletal Ageing
20 Research, School of Life Sciences, University of Nottingham, Queen's Medical Centre,
21 Nottingham NG7 2UH, UK

22 g Medical Clinic, DRK-Kliniken Nordhessen, Kassel, Germany

h Division of Gastroenterology and Hepatology, Krankenhaus Rudolfstiftung,
Krankenanstaltenverbund Wien (KAV), Vienna, Austria

j AMB-Praxis-MagenDarm Basel, Basel, Switzerland

k Department of Nutrition and Dietetics, Royal Surrey County Hospital NHS Foundation
Trust, Guildford, UK

l Centre for Nutrition and Bowel Disease, Department of Gastroenterology, Aalborg
University Hospital, Faculty of Health, Aalborg University, Aalborg, Denmark

m Department of Gastroenterology & Hepatology, Amsterdam Gastroenterology and
Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

n Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany

Corresponding address: Marianna.arvanitaki@erasme.ulb.ac.be

Keywords: Acute pancreatitis, Chronic pancreatitis, pancreatic diseases, nutrition,
nutritional support, medical nutrition

39 Abbreviations:

40 ACS, Acute Compartmental Syndrome; ANP, Acute Necrotizing Pancreatitis; AP, Acute
41 Pancreatitis; BMI, Body Mass Index; CP, Chronic Pancreatitis; DPEJ, Direct Percutaneous
42 Endoscopic Jejunostomy; DXA, Dual-energy X-ray Absorptiometry; EN, Enteral
43 Nutrition; IAH, Intra-abdominal Hypertension; IAP, Intra-abdominal Pressure; MCT,
44 Medium Chain Triglycerides; MUST, Malnutrition Universal Screening Tool; NAFLD, Non
45 Alcoholic Fatty Liver Disease; ONS, Oral Nutritional Supplements; PEG-J, Percutaneous
46 Endoscopic Gastrostomy with Jejunal Extension; PEI, Pancreatic Exocrine Insufficiency;
47 PERT, Pancreatic Enzyme Replacement Therapy; PN, Parenteral Nutrition; PPI, Proton
48 Pump Inhibitor; RCT, Randomized Controlled Trial; SIBO, Small Intestinal Bacterial
49 Overgrowth; VARD, Video-assisted Retroperitoneal Debridement;

Abstract

Both acute and chronic pancreatitis are frequent diseases of the pancreas, which, despite being of benign nature, are related to a significant risk of malnutrition and may require nutritional support. Acute necrotizing pancreatitis is encountered in 20% of patients with acute pancreatitis, is associated with increased morbidity and mortality, and may require artificial nutrition by enteral or parenteral route, as well as additional endoscopic, radiological or surgical interventions. Chronic pancreatitis represents a chronic inflammation of the pancreatic gland with development of fibrosis. Abdominal pain leading to decreased oral intake, as well as exocrine and endocrine failure are frequent complications of the disease. All of the above represent risk factors related to malnutrition. Therefore, patients with chronic pancreatitis should be considered at risk, screened and supplemented accordingly. Moreover, osteoporosis and increased fracture risk should be acknowledged in patients with chronic pancreatitis, and preventive measures should be considered.

1. Introduction

Acute pancreatitis (AP) is the most common acute gastrointestinal disease requiring hospital admission (1), with the outcome being favorable in most cases (80%) (2). However, acute necrotizing pancreatitis (ANP) may develop in up to 20% of patients and is associated with significant rates of early organ failure (38%), need for intervention (38%), and death (15%) (2). Catabolism is very high in this setting; therefore, nutritional support is one of the cornerstones of management (3). A significant amount of research has shown the superiority of enteral over parenteral nutrition in ANP, creating a paradigm shift a decade ago and modifying the management strategy (3). Nevertheless, additional questions regarding the timing, route and type of enteral nutrition (EN), as well as the place of oral refeeding, are still the objects of clinical investigations.

Chronic pancreatitis (CP) is a disease in which recurrent inflammatory episodes lead to replacement of the pancreatic parenchyma by fibrous connective tissue (4). The major consequence of CP is the loss of functional exocrine and endocrine pancreatic tissue, thus resulting in both exocrine and endocrine insufficiency (4). Pain is also frequently encountered in patients with CP, and seems to be related to a multitude of factors such as pancreatic neural remodeling and neuropathy, increased intraductal and parenchymal pressure, pancreatic ischemia and acute inflammation during an acute relapse (5). Both pain and loss of pancreatic function can lead to malnutrition in patients with CP (4). Moreover, other long-term consequences such as osteoporosis are frequently overlooked, despite their potential impact on quality of life in patients with CP. Therefore, screening for malnutrition and nutritional support play a crucial part in the multimodal management required in this setting.

Although recent guidelines for AP (2) and CP (4) have been published, a dedicated consensus on nutritional support in pancreatic diseases is lacking.

2. Methods

The present guideline was developed according to the standard operating procedure for ESPEN guidelines (6). The guideline was developed by an expert group of 13 authors from eleven European countries.

Methodology of guideline development

Based on the standard operating procedures for ESPEN guidelines and consensus papers, the first step of the guideline development was the formulation of so-called PICO questions which address specific **p**atient groups or **p**roblems, **i**nterventions, **c**ompare different therapies and are **o**utcome-related (6). In total, 31 PICO questions were created and split into two main chapters, “Acute pancreatitis” and “Chronic Pancreatitis”. To answer these PICO questions, a literature search was performed to identify suitable meta-analyses, systematic reviews and primary studies, published from 1977 up to December 2018. The PICO questions were allocated to subgroups/experts for the different subjects who created 42 recommendations and seven statements. For grading the literature, the grading system of the Scottish Intercollegiate Guidelines Network (SIGN) was used (7). Allocation of studies to the different levels of evidence is shown in Table 1. Supportive of the recommendations, the working group added commentaries to the recommendations where the bases of the recommendations are explained.

The recommendations were graded according to the levels of evidence assigned (Table 2). The wording of the recommendations reflect the grades of recommendations, level A is indicated by “shall”, level B by “should” and level 0 by “can/may”. The good practice

point (GPP) is based on experts' opinions due to the lack of studies, here, the wording can be chosen deliberately.

Online voting on the recommendations was performed on the guideline-services.com platform. All ESPEN members were invited to agree or disagree with the recommendations and to comment on them. A first draft of the guideline was also made available to the participants; on that occasion 36 recommendations and all seven statements reached an agreement of >90%, six recommendations reached an agreement of 75-90% and no recommendation an agreement of <75%. Those recommendations with an agreement of >90%, which means a strong consensus (Table 3) were passed directly; all others were revised according to the comments and voted on again during a consensus conference, which took place on 29th April 2019. All recommendations received an agreement of >90%. During the consensus conference, one of the original recommendations was considered redundant and one statement was transformed into a recommendation. Therefore, the guideline comprises 42 recommendations and six statements. To support the recommendations and the assigned grades of recommendation, the ESPEN guideline office created evidence tables of relevant meta-analyses, systematic reviews and randomized controlled trials (RCTs). These evidence tables are available online as supplemental material to this guideline.

Search strategy

A comprehensive literature research including systematic reviews, controlled clinical trials and cohort studies, with the keywords and filters presented in Table 4 was performed. We initially searched Pubmed, Cochrane Library and EMBASE for recent, rigorous systematic reviews and meta-analyses that answered our clinical questions. In the absence of these, we looked for comparative studies, whether randomized or not.

The search phrases included the following terms: (acute pancreatitis OR acute necrotizing pancreatitis OR chronic pancreatitis OR pancreatitis OR hypertriglyceridemic pancreatitis OR hyperlipidemic pancreatitis) AND (nutritional status OR nutritional assessment OR nutritional screening OR malnutrition OR oral feeding OR enteral nutrition OR tube feeding OR parenteral nutrition OR intravenous nutrition OR timing OR formula OR formulation OR nasogastric tube OR nasojejunal tube OR digestive intolerance OR necrosectomy OR minimally invasive OR increased intra-abdominal pressure OR abdominal compartment syndrome OR open abdomen OR immunonutrition OR glutamine OR antioxidants OR probiotics OR enzyme supplementation OR enzyme replacement therapy OR micronutrients OR macronutrients OR nutrient deficiency OR diet OR fat OR nitrogen OR dietary protein OR carbohydrates oral supplementation OR medium chained triglycerides OR osteoporosis OR osteopenia).

Finally, 88 articles were selected for the AP chapter, and 111 articles for the CP chapter.

3. Results

I. Acute pancreatitis

1. Which patients with AP are considered at nutritional risk?

Statement 1

Patients with AP should be considered at moderate to high nutritional risk, because of the catabolic nature of the disease and because of the impact of the nutritional status for disease development.

Strong consensus (97% agreement)

Recommendation 1

All patients with predicted mild to moderate AP should be screened using validated screening methods such as the Nutritional Risk Screening – 2002 (NRS-2002); however, the patients with predicted severe AP should always be considered at nutritional risk.

Grade of Recommendation B – Strong consensus (100% agreement)

Commentary

Fortunately, the majority of patients with AP have predicted mild or moderately severe forms of the disease that are self-limited with fully recovery in less than a week, in whom oral feeding can be started within few days after the onset of AP (9). Gut-barrier dysfunction may occur in up to 60% of patients with AP; mostly in severe AP and it is thought to lead to bacterial translocation and infection of necrosis (10). Along with the increased catabolic state related to the disease, patients with predicted severe AP are

considered at nutritional risk (11). Nevertheless, malnourished patients should also be considered at nutritional risk, even if they have predicted mild AP, because of their pre-existing condition. Similarly, patients with increased alcohol consumption are frequently malnourished (12). Scoring systems such as the NRS 2002 (13), can be helpful in identifying these patients (14-17). These scores have been validated in hospitalized, as well as critically ill patients. Nevertheless, no studies have validated these scoring systems in a specific population of patients with AP (18).

A low body mass index (BMI) may also identify patients who are at nutritional risk. Nevertheless, obesity is a known risk factor for severe AP and is, therefore, a disease severity-related nutritional risk (19).

2. Is early oral feeding feasible in patients with predicted mild AP?

Recommendation 2

Oral feeding shall be offered as soon as clinically tolerated and independent of serum lipase concentrations in patients with predicted mild AP.

Grade of Recommendation A – Strong consensus (100% agreement)

Recommendation 3

Low-fat, soft oral diet shall be used when reinitiating oral feeding in patients with mild AP.

Grade of Recommendation A – Strong consensus (100% agreement)

Commentary

Most patients with AP suffer from disease of a mild to moderate severity, non-necrotizing type with an uncomplicated clinical course. Four RCTs have shown that patients with mild to moderate AP can tolerate early oral feeding and this strategy is related with a shorter length of stay compared with conventional oral feeding (introduced after enzyme decrease, pain resolution and bowel movement) (9, 20-23). Furthermore, one of these trials revealed that oral food intake is safe and well-tolerated independently of the course and normalization of serum lipase (20). Immediate oral feeding with a soft diet seems to be more beneficial regarding caloric intake and equally tolerated compared with clear liquid diets (23-25). A meta-analysis confirmed that early oral feeding was feasible in patients with predicted mild AP and reduced length of stay (26). A recent meta-analysis including 17 studies identified that 16.3% of patients with AP will subsequently have intolerance to oral feeding (27). Predictive factors included the presence of pleural effusions and/or collections and severity (higher Ranson/Glasgow and Balthazar scores).

Hyperlipidemia is the third most common cause of AP and accounts for 4-10% of cases (28). It was reported that hyperlipidemia is associated with a worse prognosis of AP than other etiological factors (28-30). The initial management of hyperlipidemic AP is the same as for all other causes of the disease, but subsequent management in addition to generalized supportive measures may include etiology-specific targeted therapies. These include initially putting patients on a nil by mouth regimen for 24-48 hours, subsequent dietary modifications, medical management with the different classes of anti-hyperlipidemic agents, in-hospital pharmacological treatment with insulin and/or heparin and plasmapheresis. Whilst these measures are effective in lowering triglyceride concentrations, they do not appear to affect the outcome of AP (28, 29). However, tight regulation of triglyceride concentration after presentation with AP was

found to reduce the risk of recurrence. These include a low fat diet, encouragement of weight loss and treatment with a fibrate, with the addition of a statin if hypercholesterolemia is present in addition to hypertriglyceridemia (28).

3. If required, what type of medical nutrition (enteral or parenteral) is preferable in patients with AP?

Recommendation 4

In patients with AP and inability to feed orally, EN shall be preferred to parenteral nutrition (PN).

Grade of Recommendation A – Strong consensus (97% agreement)

Commentary

EN is supposed to preserve the integrity of the gut mucosa, stimulate intestinal motility, prevent bacterial overgrowth, and increase the splanchnic blood flow (10). Currently there are twelve RCTs and eleven systematic reviews/meta-analyses including a Cochrane-standard meta-analysis which clearly prove that in patients with severe AP, EN is safe and well-tolerated, with significant decreases in complication rates, multi-organ failure, and mortality, compared with PN (31-41). The meta-analysis by Al-Omran *et al.* was performed to Cochrane-standards on the basis of eight RCTs with 348 patients and clearly shows that early EN when compared with initial total PN, significantly decreases mortality by 50% (OR 0.50 [95% CI 0.28 to 0.91]), rate of infection (OR 0.39 [95% CI 0.23 to 0.65]), multi-organ failure (0.55 [95% CI 0.37 to 0.81]) as well as the necessity for operation (OR 0.44 [95% CI 0.29 to 0.67]) (35). Furthermore if only patients with severe AP were included in this meta-analysis, mortality further decreased

by more than 80% [0.18 [95 % CI 0.006 to 0.58]] (35). These results were confirmed by more recent meta-analyses, including a latest publication including only critically ill patients with AP (39). Compared with PN, EN was associated with a significant reduction in overall mortality (RR 0.36, 95% CI 0.20 to 0.65, $p=0.001$) and the rate of multiple organ failure (RR 0.39, 95% CI 0.21 to 0.73, $p=0.003$).

4. What is the optimal timing for initiating EN in patients with AP?

Recommendation 5

EN should be started early, within 24-72 hours of admission, in case of intolerance to oral feeding

Grade of Recommendation B – Strong consensus (92% agreement)

Commentary

Several meta-analyses have investigated the clinical effects and tolerance of early EN in patients with AP either within 24 hours (42-44) or 48 hours (45-47) of admission. All these meta-analyses clearly reveal that early EN is feasible, safe and well-tolerated and associated with substantial clinical benefits regarding mortality, organ failure and infectious complications for both time-points compared with delayed EN. Nevertheless, a potential bias could be that five of these meta-analysis included studies which had patients receiving PN in their control groups (42-46). One meta-analysis, compared early (within 24 hours) with late enteral nutrition (after 72 hours), but no comparison was made between 24 and 48 hours (44).

In contrast to these data from the aforementioned meta-analyses that provided strong evidence for early EN within 24-48 hours, a multicenter RCT (208 patients with

predicted severe AP) found no difference in the rate of major infection or death between early EN, started within 24 hours after admission, and an oral diet initiated 72 hours after admission (48). A second RCT (214 patients with AP) confirmed these results, showing no significant reduction in persistent organ failure and mortality in patients receiving early EN compared with patients receiving no nutritional support (49). A plausible explanation could be that these trials included mostly patients with mild or moderate AP (in the Bakker trial there were only 63% of cases with necrotizing AP (48)); therefore, the beneficial effect of early EN could be less pronounced. Finally, a prospective cohort study including 105 patients with AP concluded that the third day after hospital admission was the best cut-off time for early EN (with an area under the curve of 0.744), by reducing the risk of secondary infection and improving the nutritional status of patients, with a better tolerance (50).

5. What type of EN is indicated?

Recommendation 6

In patients with AP a standard polymeric diet shall be used.

Grade of Recommendation A – Strong consensus (97% agreement)

Commentary

Most studies that evaluated the clinical benefits of early EN in comparison with total PN used semi-elemental formulae while the recent studies were performed with polymeric formulae. In all studies both types of formulae were proven to be feasible, safe and well-tolerated. One small RCT in 30 patients found that both formulae were safe and well-tolerated (based on a visual analogue scale and number of stools per day) with some

clinical benefits for semielemental diets, including length of stay (23 ± 2 vs. 27 ± 1 days, $p = 0.006$) and weight maintenance (51). On the other hand an indirect adjusted meta-analysis of Petrov *et al.* on 428 patients using PN as a reference treatment showed no differences regarding tolerance, rate of infection and mortality between both formulae (52). Finally, a second, more recent meta-analysis, including 15 trials (1376 participants), showed no evidence to support a specific enteral formula (53). Nevertheless, a subgroup of patients with severe AP may have malabsorption and therefore, semi-elemental diets could be of interest.

6. What route should be used for EN in patients with AP?

Recommendation 7

If EN is required in patients with AP, it should be administered via a nasogastric tube. Administration via a nasojejunal tube should be preferred in case of digestive intolerance.

Grade of Recommendation B – Strong consensus (95% agreement)

Commentary

Three RCTs compared nasojejunal with nasogastric support route in patients with severe AP (54-56) showed no differences regarding tolerance, complications rates and mortality. Four meta-analyses (57-60) conclude that nasogastric tube feeding is feasible, safe and well-tolerated and, compared with nasojejunal tube feeding, does not increase complication rate, mortality, refeeding pain recurrence or prolong hospital stay in patients with severe AP. Compared with nasojejunal tubes, nasogastric tubes are much easier to place, more convenient and cheaper. Nevertheless, about 15% of patients will

experience digestive intolerance, mostly because of delayed gastric emptying and gastric outlet syndrome (57, 58) and in this situation, nasojejun tube feeding is required. Furthermore, potential bias arises from the small number of patients included in the aforementioned trials and the use of different criteria to define severe AP.

7. In patients with AP, when should PN be initiated?

Recommendation 8

PN should be administered in patients with AP who do not tolerate EN or who are unable to tolerate targeted nutritional requirements, or if contraindications for EN exist.

Grade of Recommendation GPP – Strong consensus (97% agreement)

Commentary

The primary nutritional route in all patients with severe AP should be enteral, as this route has been shown to have benefits over other regimens. However, PN is indicated in patients with severe AP who do not tolerate EN or who are unable to tolerate targeted requirements, or if there exists contraindication for EN overall. Complications of severe AP, which may occur and represent a contraindication for EN, include bowel obstruction, abdominal compartment syndrome, prolonged paralytic ileus and mesenteric ischemia (61). Similar to critically ill patients with other diseases, approximately 20% of patients with severe AP have complications, which are associated with absolute or relative contraindications for EN (Figure 1) (17).

8. How should medical nutrition be provided in case of necrosectomy (endoscopically or by minimally invasive surgery) in patients with severe AP?

Recommendation 9

Oral food intake in patients undergoing minimally invasive necrosectomy is safe and feasible and should be initiated in the first 24 hours after the procedure, if the clinical state (hemodynamic stability, septic parameters, gastric emptying) of the patient allows it.

Grade of Recommendation GPP – Strong consensus (95% agreement)

Recommendation 10

In patients undergoing minimally invasive necrosectomy who are unable to be fed orally, EN is indicated via nasojejunal as preferred route.

Grade of Recommendation B – Strong consensus (91% agreement)

Recommendation 11

PN is indicated in patients undergoing minimally invasive necrosectomy who do not tolerate EN or who are unable to tolerate targeted nutritional requirements, or if there exist contraindications for EN.

Grade of Recommendation GPP – Strong consensus (94% agreement)

Commentary

Approximately 10-20% of patients with AP will develop necrosis of the pancreas and/or peripancreatic tissue (ANP) (1, 2). These patients with ANP have moderate or severe forms of AP, and a higher risk for development of multiple organ failure, secondary infection of the necrosis, and death (62). After proven benefits of the “step-up” (minimally invasive approach) over the open approach for the treatment of ANP (63), minimally invasive techniques have been used extensively (64). Furthermore, the Dutch Pancreatitis Study Group recently showed a lower rate of pancreatic fistula and better cost benefits of endoscopic over surgical step-up approach for infected necrotizing pancreatitis (65). Unfortunately, to date there are no published data on nutritional support in patients with AP treated by the minimally invasive approach. In the aforementioned trial (65), all patients received oral nutrition, if tolerated. If this was not tolerated, a nasojejunal feeding tube was introduced and EN was started. If gastrointestinal feeding was contraindicated, the patient received PN. No specific data were reported regarding nutrition-related outcomes.

In the RCT by Bakker *et al.* (48), there was no superiority of early (first 24 hours) nasojejunal tube feeding when compared with an oral diet after 72 hours in reducing the rate of infection or death in patients with predicted severe AP. In this trial interventional procedures due to necrotizing pancreatitis included percutaneous catheter drainage, endoscopic transgastric drainage or necrosectomy and surgical necrosectomy (without information on the type of surgery performed – minimally invasive or open approach). The authors did not find any difference in the number of patients who underwent interventions between groups (24 percutaneous drainages in early EN group vs. 46 in the on demand feeding group, $p = 0.13$; eight endoscopic transgastric drainage or necrosectomy in the early EN group vs. six in the on-demand feeding group, $p = 0.53$; and three surgical necrosectomy in the early EN group vs. seven in the on-demand

feeding group, $p = 0.49$). In this trial PN was not used, as it was not mentioned in the feeding protocol of the study. In a retrospective series of 37 patients undergoing laparoscopic transgastric necrosectomy, an oral food intake 24-48 hours after the procedure was feasible and safe (66). In one prospective study on video-assisted retroperitoneal debridement (VARD) the feeding regimen was reported but without specified time of initiation and reasons for shifting oral nutrition to EN or PN (67). Forty patients in that study were fed by nasojejunal tube as the preferred route when tolerated; otherwise, PN was given (67). Therefore, based on small series, nasojejunal feeding seems safe in patients having undergone minimally invasive necrosectomy. Nevertheless, definitive data are missing.

9. How should medical nutrition (EN and PN) be provided in critically patients with severe AP (intra-abdominal hypertension (IAH), abdominal compartment syndrome (ACS) with need for open abdomen)?

Recommendation 12

In patients with severe AP and intraabdominal pressure (IAP) < 15 mmHg early EN shall be initiated via nasojejunal, as the preferred route, or nasogastric tube. IAP and the clinical condition of patients during EN shall be monitored continuously.

Grade of Recommendation A – Strong consensus (91% agreement)

Recommendation 13

In patients with severe AP and IAP > 15 mmHg EN should be initiated via nasojejunal route starting at 20 mL/hour, increasing the rate according to the tolerance. Temporary reduction or discontinuation of EN should be considered when IAP values further increase under EN.

Grade of Recommendation B – Strong consensus (94% agreement)

Recommendation 14

In patients with severe AP and IAP > 20 mmHg or in the presence of ACS, EN should be (temporarily) stopped and PN should be initiated.

Grade of Recommendation GPP – Strong consensus (94% agreement)

Recommendation 15

In patients with severe AP and open abdomen EN should be administered, at least in a small amount. If required for achievement of nutritional requirements, supplementary or total PN should be added.

Grade of Recommendation B – Strong consensus (97% agreement)

Commentary

The mortality of patients with severe AP who develop IAH/ACS during the course of the disease rises from 25% up to 66% (68, 69). Energy expenditure in patients with AP is increased by 1.49 (1.08 to 1.78) × the predicted resting energy expenditure; 58% of

patients with severe AP have an increase in energy expenditure, approximate net nitrogen losses are 20-40 grams per day, and proteolysis can be increased by 80% (70, 71). There are no data available regarding energy requirements in patients with both AP and IAH/ACS, however, energy expenditure in such patients may be increased due to several reasons (decreased splanchnic blood flow, acidosis and bacterial translocation) (17, 72).

It has been clearly demonstrated that EN in patients with severe AP reduces mortality and infectious complications, decreases organ failure and surgical intervention rate, has a trend towards reduction of hospital stay, and is safer and more effective than PN (17). Nevertheless, it has been reported that EN may increase intraluminal pressure with subsequent elevation of IAP and development of severe complications (73, 74). Therefore, it is recommended that EN should be administered with caution when IAP reaches 15 mmHg and over (74). In an observational study, 274 patients with AP had IAH and 103 developed ACS. The intolerance of EN was more frequent in patients with grade III and IV IAH (n=105) and 62/105 (59%) required PN (75). In only one RCT including 60 patients, comparing early with delayed EN in patients with IAH and severe AP, it was found that early EN had benefits in patients with IAP < 15 mmHg preventing development of IAH. In patients with IAP above 15 mmHg abdominal distension was more frequent in the early EN group. The group of patients with early EN experienced feeding intolerance more often than patients in delayed EN group. However, early EN did not increase IAP and was able to ameliorate clinical course of the disease (76). Because the majority of patients with IAH have gastrointestinal symptoms and signs (absence of bowel movements, abdominal distension, high gastric residual volume, etc.), EN should be initiated via nasojejunal tube (77). From a practical point of view, in patients with severe AP and IAH the initiation of EN should be at 20 mL/hour, increasing

the rate according to the tolerance. The reduction of EN from higher rates to 20 mL/h should be considered when IAP increases between 15 and 20 mmHg. In patients with IAP above 20 mmHg or in the presence of ACS, EN should be (temporarily) stopped (74). When it is impossible to meet nutritional goals with EN only, supplementary or total PN should be considered.

A decompressive laparotomy (laparostomy) may be necessary in up to 74% of patients who develop ACS during course of AP (72). Patients with an open abdomen are in a hyper-catabolic state with high nitrogen losses and negative nitrogen balance. It has been estimated that such patients have nitrogen loss of almost 2 g/L of abdominal fluid output and, therefore, nutritional therapy in patients with an open abdomen is essential (78). Several cohort studies reported that initiation and feeding by EN was feasible and safe despite a relatively high rate of digestive intolerance, ranging from 48-67% (78-83). Two studies concluded that that early EN in patients with an open abdomen resulted in higher fascial closure rates, lower fistula rates, reduced nosocomial infections and lower hospital costs (82, 83). In the multicenter analysis by Burlew *et al.*, out of 597 with an open abdomen patients, EN was successfully initiated in 39% (81). For the 307 patients without a bowel injury, logistic regression indicated that EN was associated with higher fascial closure rates (OR 5.3; $p < 0.01$) decreased complication rates (OR, 0.46; $p = 0.02$), and decreased mortality (OR 0.30; $p = 0.01$) (81).

10. Is there any role for immunonutrition (glutamine, antioxidants) in severe AP?

Recommendation 16

When EN is not feasible or contraindicated and PN is indicated, parenteral glutamine should be supplemented at 0.20 g/kg per day of L-glutamine. Otherwise, there is no role for immunonutrition in severe AP.

Grade of Recommendation B – Strong consensus (94% agreement)

Commentary

An initial meta-analysis including eleven RCTs assessed the effect of antioxidants (five RCTs on glutamine and six on various other antioxidants) on the outcome of patients with AP (84). Among patients with AP, antioxidant therapy resulted in a borderline significant reduction in hospital stay (mean difference 1.74; 95% CI 3.56 to 0.08), a significant decrease in complications (RR 0.66; 95% CI 0.46 to 0.95) and a non-significant decrease in mortality rate (RR 0.66; 95% CI 0.30 to 1.46). Nevertheless, these results were mostly attributed to the effect of glutamine. Recently, a Cochrane Review assessed the effects of different pharmacological interventions including antioxidants in patients with AP (85). Very low-quality evidence suggested that none of the pharmacological treatments decreased short-term mortality in patients with AP.

Regarding glutamine, four meta-analyses have been published. A meta-analysis of ten RCTs including 433 patients with severe AP revealed a significant decrease in the incidence of infectious complications and mortality in the patient group with glutamine-enriched nutrition (86). Another meta-analysis of twelve RCTs (including 505 patients) demonstrated a significantly reduced infection rate and mortality after glutamine supplementation in patients with AP (87). In the subgroup analyses, only patients who received total PN demonstrated a significant benefit in terms of study outcomes. Two

recently published meta-analyses showed beneficial effects of glutamine supplementation in patients with AP in the terms of elevation of serum albumin concentrations, decrease in serum concentrations of C-reactive protein, and reductions in infectious complications, mortality and hospital stay (84, 88). Nevertheless, the risk of bias of the included studies is important due to many reasons: (i) small sample size in most of the studies, (ii) possible heterogeneity in disease severity and (iii) confounding factors such as other interventions that may change outcome (drainage, debridement or surgery).

11. Is there any role for probiotic use in severe AP?

Recommendation 17

Probiotics cannot be recommended in patients with severe AP.

Grade of Recommendation 0 – Consensus (89% agreement)

Commentary

A meta-analysis of six RCTs including 536 patients revealed no significant benefit of probiotics on pancreatic infection rate, overall infection rate, operation rate, length of hospital stay and mortality (89). Significant heterogeneity was observed in the type, dose and treatment duration of probiotics in these trials. In one of these RCTs the patient group assigned to a particular combination of probiotic strains showed similar pancreatic infection rate but increased mortality when compared with the placebo group (90).

12. Is there any role for the use of oral enzyme supplementation in AP?

Recommendation 18

Pancreatic enzymes should not be supplemented generally except in patients with obvious pancreatic exocrine insufficiency (PEI).

Grade of Recommendation B – Strong consensus (97% agreement)

Commentary

There are only two RCTs with a total of 78 patients randomized to pancreatic enzyme supplementation or placebo (91, 92). In the study by Kahl *et al.* 20 of the 56 patients showed low fecal elastase values indicating PEI. Although the pancreatic enzyme supplement group showed a tendency for better outcome this did not reach statistical significance (91). In the second small study by Patankar *et al.* there was also no significant difference in laboratory or clinical outcomes (92). Therefore, no conclusion can be drawn, but enzyme supplementation should be considered in patients with proven or obvious exocrine insufficiency and malabsorption with steatorrhea.

II. Chronic pancreatitis

13. What are the risks of developing malnutrition in patients with CP?

Statement 2

Risk of malnutrition in CP is high and malnutrition is common in patients with CP.

Strong consensus (100% agreement)

Commentary

CP is a disease with progressive and irreversible inflammatory changes in the pancreas that result in permanent structural damage with fibrosis, which can lead to abdominal pain and to impairment of exocrine (pancreatic insufficiency) and often endocrine function (4, 93-95).

Malnutrition is often a late, but important manifestation in the course of CP and depends on the intensity and duration of the underlying disease. There are differences in the onset of pancreatic insufficiency and malnutrition between patients with alcoholic and idiopathic CP. The latency between onset of first symptoms and signs of CP, including pain and malabsorption/malnutrition is between five to ten years in alcoholic, but delayed in non-alcoholic pancreatitis (94).

Despite the inconsistency of the data there is an evident risk of malnutrition in patients with CP (95-97). According to a recent study medium or higher risk for malnutrition based on Malnutrition Universal Screening Tool (MUST) score of one or higher was found in 31.5% patients (98). Similarly, 26% underweight patients with a nutritional risk were identified in a study of outpatients with CP (99).

At the same time a recent prospective cohort study on 62 patients with CP and 66 controls showed that over half of the patients with CP were overweight or obese (100). Nevertheless, significant differences in handgrip strength were shown in patients with CP when compared with controls.

In patients with CP with moderate to severe weight loss, decreased lean body mass and sarcopenia may lead to decreased functional capacity, which may have an impact on quality of life (101, 102). In addition, PEI leads to the increased risk of developing significant bone loss and severe osteoporosis (103, 104). A recent prospective study (102) including 182 patients with CP showed that sarcopenia was present in 17% (74% of patients with CP had a BMI > 18.5 kg/m²). During follow-up, sarcopenia was associated with an increased risk of hospitalization (OR 2.2; 95% CI 0.9 to 5.0; p = 0.07), increased number of in-hospital days (p < 0.001), and reduced survival (HR 6.7; 95% CI 1.8 to 25.0; p = 0.005).

14. What are the causes of malnutrition in patients with CP?

Statement 3

Pancreatic insufficiency, abdominal pain, alcohol abuse, lower food intake, diabetes mellitus and smoking are the main causes of malnutrition in CP.

Strong consensus (97% agreement)

Commentary

Multiple risk factors for developing nutrient deficiencies and malnutrition co-exist in patients with CP. First of all, pancreatic insufficiency (exocrine but also often endocrine) can lead to maldigestion and malabsorption. Clinical signs of PEI include steatorrhea,

abdominal pain, weight loss and malnutrition (4). Recent data showed endocrine insufficiency and/or clinical steatorrhea in 41% and 36% of 809 patients (93). Moreover, increased resting energy expenditure can be seen in up to 50% of patients with CP, thus leading to a negative energy balance and malnutrition (105). Furthermore, abdominal pain, which is frequent in patients with CP, can lead to suboptimal dietary intake and also contribute to malnutrition (4).

Tobacco is an independent risk factor for CP, and can also be a disease modifier, acting in synergy with alcohol intake, and therefore, adds to the nutritional risk factors (93).

15. Which diagnostic tests are preferred to assess nutritional status in patients with CP?

Recommendation 19

Nutritional status should be assessed according to symptoms, organic functions, anthropometry, and biochemical values. Solely BMI should not be used, because it does not register sarcopenia in the obese patient with CP.

Grade of Recommendation GPP – Strong consensus (97% agreement)

Commentary

Studies assessing malnutrition have identified many biochemical factors that are associated with malnutrition (106, 107) and prevalence studies show a diverse presentation of malnutrition. Olesen *et al.* identified that 26% of patients with CP were underweight in a cross-sectional study of 166 patients with CP (99), whereas Duggan *et al.* highlighted that over half of the patients in their prospective controlled cohort study (n = 128) fell into the overweight/obese category using BMI (100). However, patients had lower muscle stores and reduced functional status assessed using hand-grip

strength than healthy controls. Consequently, BMI alone is not considered an adequate method of assessing nutritional status. Percentage weight loss is considered a more reliable indicator of the onset of malnutrition and is associated with an increased risk in the surgical setting (108).

Consequently, nutritional assessment should allow for detection of simple malnutrition, sarcopenia and micronutrient deficiencies in addition to identifying symptoms that may predispose patients to worsening malnutrition (Error! Reference source not found.5).

16. What is the frequency of screening for micro- and macro-nutrient deficiencies in patients with CP?

Recommendation 20

Patients should undergo screening for micro- and macronutrient deficiencies at least every twelve months; screening may need to occur more frequently in those with severe disease or uncontrolled malabsorption.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Commentary

Patients with CP are at high risk of malnutrition, both in terms of body weight and altered body composition (100). This has an impact on quality of life (99) and survival after surgery (109, 110). Nutritional intervention can improve nutritional markers and is associated with reduced pain (111) and, therefore, routine screening to trigger nutritional intervention should be undertaken. Deficiencies in micronutrients (vitamin B12, folic acid, vitamin A, D and E, zinc, selenium, iron) are well documented in patients with exocrine insufficiency, these are diverse in presentation with some studies

reporting biochemical deficiencies (100, 103, 112) and case reports document clinical manifestations including night blindness (113, 114). However, there are no data recommending the frequency of assessment or the likely timing of progression to micronutrient deficiency. As clinical manifestation of deficiency represents a late presentation, routine screening should be implemented to detect early signs of deficiency.

17. What recommendations regarding diet and intake of fat, carbohydrates and proteins should be given in patients with CP?

Statement 4

Patients with CP do not need to follow a restrictive diet.

Strong consensus (94% agreement)

Recommendation 21

CP patients with a normal nutritional status should adhere to a well-balanced diet.

Grade of Recommendation GPP – Strong consensus (94% agreement)

Recommendation 22

Malnourished patients with CP should be advised to consume high protein, high-energy food in five to six small meals per day.

Grade of Recommendation GPP – Strong consensus (94% agreement)

Recommendation 23

In patients with CP, diets very high in fiber should be avoided.

Grade of Recommendation B – Strong consensus (91% agreement)

Statement 5

In patients with CP, there is no need for dietary fat restriction unless symptoms of steatorrhea cannot be controlled.

Strong consensus (100% agreement)

Commentary

There are very little data to suggest the optimal dietary management for patients with CP. Historically, patients were encouraged to have a low-fat diet, and studies in the Netherlands suggest 48-58% of patients still restrict dietary fat (104, 115). International guidelines are consistent in their recommendation that patients should have a balanced diet and avoid fat restriction (4, 116-119).

The role of dietary fat has been examined in small studies, suggesting an improvement in dyspeptic symptoms in patients with very mild pancreatic disease who did not consume alcohol regularly when a very low fat diet was consumed (< 20 g fat per day) (120) and patients who consumed a higher fat diet were thought to be diagnosed at a younger age, and had an increased probability of continuous abdominal pain (121) suggesting a potential role in the initial development of CP. However once CP was diagnosed, there was no difference in severity or complications of disease. An RCT comparing dietary counselling and nutritional supplements in a cohort of 60

malnourished patients with CP found that nutritional intervention in which 33% of energy was derived from fat was well tolerated (111). Improvements in nutritional status and pain control were observed in patients receiving nutritional intervention and the authors did not report any adverse events (111).

Patients consuming very high fiber diets reported increased flatulence, and increased fecal weight and fat losses were observed in a small trial (n = 12) in patients with CP. This study suggested that very high fiber diets may inhibit pancreatic enzyme replacement therapy, thus resulting in malabsorption. Thus, very high fiber diets are not recommended in this patient group (122).

18. Are oral supplements, with or without medium-chain triglycerides (MCTs), indicated in patients with CP?

Recommendation 24

Oral nutritional supplements (ONS) should be prescribed to undernourished patients only if oral nutrition is insufficient for reaching the calorie and protein goals.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Recommendation 25

If adequate enzyme supplementation and exclusion of bacterial overgrowth has not led to relief of malabsorption and its accompanying symptoms, ONS with MCT can be administered.

Grade of Recommendation 0 – Strong consensus (97% agreement)

Commentary

Very few studies have investigated the benefit of ONS in patients with CP. Eighty percent of patients can be treated with diet and enzyme supplementation, the rest need oral supplementation (96).

ONS can be of benefit in undernourished patients with CP, especially if the caloric and protein goals cannot be reached with normal meals and counselling. ONS are a simple way to improve oral intake, but long-term compliance may be a problem.

There are no RCTs investigating the relative efficacy of different formulae (e.g. standard or peptide-based with MCT). However, in the presence of PEI, enteral formulae consisting of pre-digested products and a mixture of long chain fatty acids and MCT would seem, theoretically, to have potential advantage. MCTs are less dependent on lipase activity for their absorption (123).

A reduction in oral fat intake or the replacement of dietary fat with MCT risks a reduction in energy intake and, therefore, a negative energy balance. MCTs have an unpleasant taste and are associated with adverse effects like cramps, nausea, and diarrhea. Up to now, studies have not shown any clear benefit of MCTs over standard long-chain triglycerides when used in combination with enzyme supplementation (123, 124). One RCT investigated the efficacy of ONS in patients with CP and severe malnutrition (111). Dietary counselling achieved equal results compared with the use of a commercial supplement enriched with MCTs. Both groups also received enzyme supplementation and so it is not possible to explain the additional gain from dietary MCTs over enzyme supplementation.

If MCTs are being considered, their dose should be increased slowly depending on the patient's tolerance.

730

731 19. When is micronutrient supplementation indicated in patients with CP (not including
732 osteoporosis prevention)?

733 **Recommendation 26**

734 **Fat-soluble (A, D, E, K) and water-soluble (vitamin B12, folic acid, thiamine)**
735 **vitamins as well as minerals such as magnesium, iron, selenium and zinc should**
736 **be monitored (if available) and administered if low concentrations are detected**
737 **or if clinical signs of deficiency occur. Supplementation should be proposed to**
738 **patients with known malabsorption.**

739 **Grade of Recommendation GPP – Strong consensus (95% agreement)**

740

741 **Commentary**

742 The reported prevalence of deficiency of fat-soluble vitamins is 3–14.5% for vitamin A
743 deficiency (100, 103, 125), 58–77.9% for vitamin D deficiency (100, 103, 125, 126), 9-
744 24% for vitamin E deficiency (100, 103, 106, 125, 126) and 13–63% for vitamin K
745 deficiency (100, 103, 125, 126). In a prospective controlled cohort study of 128 subjects
746 and 66 age/gender-matched controls, 14.5% and 24.2% were deficient in vitamins A
747 and E, respectively, with a significant difference compared with controls. Nineteen
748 percent of patients had excess serum vitamin A concentrations (100). This must be
749 taken in account and a blind supplementation of all fat-soluble vitamins for all patients
750 with CPs is not advised.

751 Deficiencies of water-soluble vitamins in patients with CP are less frequent. A recent
752 study with 301 patients with CP and 266 controls showed that patients with CP had
753 significantly lower concentrations of vitamins A, D and E, but no difference regarding

vitamin B12 (103). Similarly, another cohort study of 114 patients with CP (33% with exocrine failure) did not show any significant deficiencies of vitamin B12 (0%) and folic acid (2.2%) (127).

Thiamine deficiency secondary to concomitant alcoholism must be considered (106).

Minerals and trace elements deficiencies have been reported in patients with CP in some case-control studies. The results are conflicting. Lower concentrations of zinc, selenium (106) and magnesium (127) have been observed. Furthermore, low magnesium concentrations seemed to correlate with exocrine failure (127).

20. When is EN indicated in patients with CP and how should it be administered?

Recommendation 27

EN should be administered in patients with malnutrition who are not responding to oral nutritional support.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Recommendation 28

EN should be administered via the nasojejunal route in patients with pain, delayed gastric emptying, persistent nausea or vomiting and gastric outlet syndrome.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Recommendation 29

Long-term jejunostomy access (percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) or direct percutaneous endoscopic jejunostomy (DPEJ) or surgical jejunostomy) can be used in those requiring EN for more than 30 days.

Grade of Recommendation GPP – Strong consensus (97% agreement)

Recommendation 30

Semi-elemental formulae with medium chain triglycerides can be used if standard formulae are not tolerated.

Grade of Recommendation GPP – Strong consensus (94% agreement)

Recommendation 31

Pancreatic enzymes should be supplemented in patients requiring EN, if signs of exocrine failure manifest.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Commentary

Oral nutritional support with dietary counselling is usually sufficient to improve nutritional status in patients with CP (111). EN is indicated in approximately 5% of patients with CP (97). Regarding indications and outcomes of EN in these patients, evidence is based on few cohort studies and RCTs are generally lacking (4).

Four retrospective series have shown the benefits of EN in patients with CP regarding weight gain and pain control (128-131). Two of them included 58 (129) and 50 patients

(131) respectively, in whom a naso-jejunal tube was placed. Long-term access with PEG-J or DPEJ was used in 57 (128) and 58 patients (130). All studies showed that this type of nutritional support was safe and effective in patients with CP, even in case of gastric outlet syndrome (130, 131).

There is limited high quality evidence for the composition of enteral formulae in patients with CP. However, there is a rationale that semi-elemental enteral formulae with MCTs are more adapted for jejunal nutrition, compared with polymeric formulae (132). In two of the aforementioned studies (129, 131), semi-elemental formulae were used with good digestive tolerance. Nevertheless, the cost of these feeds is higher and data on cost-effectiveness are also lacking.

In patients with exocrine failure, who do not improve with semi-elemental formulae, pancreatic enzymes can be administered with the formula (133). This involves opening the capsules and suspending the enzyme microspheres in thickened acidic fluid (such as the mildly thickened or "nectar-thick" fruit juice used for dysphagia) for delivery via the feeding tube.

21. When is PN indicated in patients with CP and how should it be administered?

Recommendation 32

PN may be indicated in patients with gastric outlet obstruction and in those with complex fistulating disease, or in case of intolerance of EN.

Grade of Recommendation GPP – Strong consensus (100% agreement)

Recommendation 33**For PN the preferable route is central venous access.****Grade of Recommendation GPP – Strong consensus (100% agreement)****Commentary**

PN is infrequently used in patients with CP (4, 97). EN preserves immune function and mucosal architecture and decreases the possibility for hyperglycemia while PN also increases the risk of catheter-related infections and septic complications (96, 119). PN is, therefore, only indicated when it is impossible to use EN (e.g. presence of gastric outlet obstruction, the need for gastric decompression, when it is impossible to introduce a tube into the jejunum, or a complicated fistula is present) or if requirements are only partly reached by EN. PN is mainly administered over a short-term period and long-term studies are lacking. In this case, a standard nutritional solution should be administered via central venous access such as a peripherally inserted central catheter. Contraindications to PN do not differ from general contraindications to medical nutrition.

22. What are the indicators for starting pancreatic enzyme replacement therapy (PERT) in patients with CP?

Recommendation 34

When PEI is diagnosed through clinical signs and symptoms and/or laboratory tests of malabsorption, PERT shall be initiated. An accurate nutritional assessment is mandatory to detect signs of malabsorption.

Grade of Recommendation A – Strong consensus (100% agreement)**Commentary**

PEI is defined as an insufficient secretion of pancreatic enzymes (acinar function) and/or sodium bicarbonate (ductal function) (4). Diagnosis of PEI can be challenging in practice because pancreatic function and secretion are not solely reliant on the quantity or quality of pancreatic tissue (134) but also depend on complex pancreatic stimulatory mechanisms (135). Moreover, different PEI biomarkers and their threshold values have been used in the current literature (136). For these reasons a wide range (from 22% to 94%) of prevalence rates for PEI among patients with CP has been reported (98, 106, 137-146).

The most frequent clinical sign of PEI is steatorrhea (147), defined as presence of fat in the stool, and associated generally with flatulence, bloating, dyspepsia, urgency to pass stools, and cramping abdominal pain. In a recent systematic review, including 14 studies on pancreatic enzyme supplementation in patients with CP, the criteria for the diagnosis of PEI were the measurement of the coefficient of fat absorption with a threshold $< 80\%$ or the fecal fat absorption less than 7 - 15 g of fat per day (136).

Overt steatorrhea is not expected unless there is severe or decompensated PEI (i.e. when secretion of pancreatic lipase is less than $< 10\%$ of normal). However, the absence of overt steatorrhea is not always an indicator of adequate absorption and nutritional status. PEI is consistently associated with biochemical and clinical signs of malnutrition (148). Management of PEI involves replacing the inadequate pancreatic enzymes, which should be used to maintain weight and improve the symptoms of maldigestion (149).

Awareness of PEI among many physicians is poor outside of referral centers and especially among physicians in primary care (115). Consequentially, patients who

present with symptoms of PEI may be overlooked or advised to adopt inappropriate dietary restrictions in an attempt to control the symptoms. A study identified that the primary unmet patient need was the difficulty in managing gastrointestinal symptoms, diet, and digestion; indeed, many of these patients and caregivers cited delays in dietary assessment and initiation of PERT causing additional distress that could have been prevented (150). Untreated PEI has also a deleterious impact on the quality of life of patients (151). As the quantitative measurement of fecal fat is often omitted, it is recommended that enzyme replacement is started when clinical signs of malabsorption, or anthropometric and/or biochemical signs of malnutrition are present (96, 127, 152-154). Symptoms include weight loss, alteration of body compartments at bioimpedance analysis, and low nutritional markers (albumin, cholinesterase, prealbumin, retinol-binding protein, and magnesium) (127). Although it is assumed that steatorrhea is the most important clinical manifestation of PEI, several studies have shown reduced absorption of fat-soluble vitamins even in patients with mild to moderate PEI (155-158). Non-alcoholic fatty liver disease (NAFLD) is also a poorly recognized complication of PEI. The mechanisms underlying NAFLD in PEI is different from NAFLD associated with metabolic syndrome, because it is mainly due to malabsorption of essential amino acids such as choline which leads to a decrease in plasma concentrations of apoprotein B (159), a major component of very-low-density lipoprotein.

23. What are the enzyme preparations of choice for PERT?

Recommendation 35

pH-sensitive, enteric-coated microspheres pancreatic enzyme replacement preparations shall be used for treating PEI.

Grade of Recommendation A – Strong consensus (100% agreement)**Commentary**

There are multiple pancreatic enzyme replacement preparations that are now licensed around the world. All are of porcine origin and contain, with varying concentrations and mixtures, pancreatic lipase, amylase, protease, and other pancreas-derived proteins and nucleic acids. Several factors affect the efficacy of pancreatic enzyme supplementation: (a) mixture with meal; (b) gastric emptying with meal; (c) mixing with chyme and bile acids and rapid release of enzymes in duodenum (160).

Nowadays, most of the pancreatic enzyme preparations are formulated as pH-sensitive, enteric-coated, capsules containing microspheres or tablets that protect the enzymes from gastric acidity and allow them to disintegrate rapidly at pH > 5.5 in the duodenum (160, 161). Non enteric-coated, conventional powder or tablet formulations have been abandoned because they are less effective in treating PEI as pancreatic enzymes are partially inactivated by pepsin and gastric acidity (162).

The efficacy of these more recent formulations has been demonstrated in several recent studies (163-166) and in a recent meta-analysis (136). A Cochrane review on the efficacy of pancreatic enzyme preparations in patients with pancreatic insufficiency demonstrated a higher efficacy for enteric-coated microspheres compared with enteric-coated tablets (167). Mini-microspheres 1.0 - 1.2 mm in diameter seem to be associated with higher therapeutic efficacy compared with 1.8 - 2.0 mm microspheres that still have an optimal therapeutic action (168). Another trial compared two enteric-coated pancreatic enzyme preparations. One moisture-resistant, formulated to contain between 90% to 110% labeled lipase content over the shelf life of the product and the other potentially unstable in the presence of moisture and degradable over time. The

characteristics of the moisture-resistant formulation should have allowed more accurate dosing, both providing more predictable therapeutic effects and reducing the risk of overdose, which is assumed as a potential risk factor for fibrosing colonopathy. The results suggested a comparable efficacy and safety in patients with cystic fibrosis for the treatment of PEI (169).

24. How should enzyme supplementation be administered?

Recommendation 36

Oral pancreatic enzymes should be distributed along with meals and snacks.

Grade of Recommendation B – Strong consensus (100% agreement)

Commentary

The efficacy of pancreatic enzyme supplements presupposes the mixing of enzymes and chyme (161). While one study evaluating the impact of the scheduling of PERT administration on fat malabsorption suggested the optimal timing of administration was during or after meals, no significant difference was observed when patients took PERT immediately before meals (170). In practice, although many patients prefer to take PERT at the beginning of meals, they should be encouraged to spread the capsules out over a meal when using multiple capsules or with larger meals (162, 170). If the patient is taking the older preparations of pancreas powder, they should take about a third of the dose immediately before, one third during, and one third immediately after the meal. This concerns only meals and snacks that contain fat (e.g. not for fruit).

25. What is the optimal dosage of enzyme supplementation?

Recommendation 37

The posology aims at individual needs and depends on the severity of the disease and the composition of the meal. In practice, a minimum lipase dose of 20,000 - 50,000 PhU (based on the preparation) shall be taken together with main meals, and half that dose with snacks.

Grade of Recommendation A – Strong consensus (100% agreement)

Commentary

The dosage recommended depends on the patient's clinical response, but the dosage and dosing will need to be monitored carefully, as well as altered, depending on patient's food intake/pattern of eating, method of cooking, portion sizes, and disease evolution.

For the digestion of a normal meal a minimum activity of 30,000 IU of naturally secreted pancreatic lipase is required. The recommended initial dose is about 10% of the physiologically secreted dose of lipase after a normal meal (171). Since 1 IU of naturally secreted lipase equals 3 PhU in commercial preparations, the minimum amount of lipase needed for digestion of a normal meal is 90,000 PhU (endogenous plus orally administered lipase).

The results of several RCTs have proven the efficacy of pancreatic enzyme replacement therapy with enteric-coated mini-microspheres at a dose ranging from 40,000 - 80,000 PhU of lipase per main meal, and half dose per snack (165, 166, 170, 172-174). Studies evaluating enteric-coated microspheres have shown a similar efficacy for doses ranging from 10,000 - 40,000 PhU of lipase per meal, indicating the lack of a dose-response relationship with these preparations (175, 176).

Dose escalation may be warranted according to response. In adults there is no upper limit to dosing, as there is no risk of overdose because pancreatic enzymes exceeding the needs are eliminated through stools. Caution for dosage should be placed in children in whom colonic strictures have been described after high dose of the enteric coated, delayed release preparations (177).

26. How should the efficacy of enzyme supplementation be evaluated?

Recommendation 38

The efficacy of PERT should be evaluated by the relief of gastrointestinal symptoms and the improvement of nutritional parameters (anthropometric and biochemical). In patients who do not respond, the evaluation should be extended to pancreatic function tests (fecal fat excretion or ¹³C-MTG-breath test).

Grade of Recommendation B – Strong consensus (97% agreement)

Commentary

The aforementioned recent meta-analysis including 14 RCTs (136) showed that PERT increased the coefficient of fat absorption, as well as improved gastrointestinal symptoms, compared with baseline or placebo. Two open label extensions up to one year from RCTs included in the meta-analysis demonstrated significant improvement in nutritional parameters and weight (164, 178). A review of reported data (106) as well as the recent guidelines on the therapy for CP (4) support the use of nutritional parameters as an optimal way to assess the efficacy of PERT. Dietary intake and nutritional status should be monitored regularly to maximize patient compliance and specialist dietetic assessment sought in patients with underlying malnutrition (179).

In patients who do not respond, pancreatic function tests (136) while on PERT can monitor effectiveness. ¹³C-MTG-breath test is a useful method that can replace the somewhat cumbersome fecal fat excretion tests and can be used for patients on PERT (180).

27. What should be done in cases of unsatisfactory clinical response?

Recommendation 39

In case of unsatisfactory clinical response, PERT dosage should be increased or a protein pump inhibitor (PPI) should be added. If these methods fail, other causes of malabsorption such as small intestinal bacterial overgrowth (SIBO) should be excluded.

Grade of Recommendation B – Strong consensus (97% agreement)

Commentary

The recommended dose of 20,000 - 50,000 PhU with main meals has been shown to improve symptoms in more than half the patients (136). Dose escalation may be warranted according to response. In adults there is no upper limit to dosing, as there is no risk of overdose because pancreatic enzymes exceeding the needs are eliminated in the stool. Caution for high PERT dosage should be exercised in children, in whom colonic strictures have been described after high dose of the enteric coated, delayed release preparations (177).

The inhibition of gastric acid secretion by PPIs can lead to a significant improvement and even normalization of fat digestion in patients with an incomplete response to PERT, as shown in a prospective cohort study of 21 patients with CP (43% had an initial

incomplete response to PERT, and 29% normalized their function after addition of a PPI) (181). Nevertheless, a review including 34 clinical trials failed to show improvement in the efficacy of PERT with PPI or histamine-2 receptor antagonists (182). It is noteworthy that the populations included and the therapeutic schemes were very heterogeneous, therefore, suggesting significant bias.

SIBO can also explain persistent symptoms. A recent prospective case-control study revealed that SIBO was present in 15% of patients with CP whereas no healthy control was tested positive by means of a fasting glucose hydrogen breath test (183).

28. Does the surgical technique for treating CP affect PERT and nutritional status?

Recommendation 40

Long-term PERT and nutritional status are similarly affected by all surgical procedures. Tissue-preserving procedures shall be preferred.

Grade of Recommendation A – Strong consensus (100% agreement)

Commentary

Surgical intervention is effective in carefully selected patients. Common indications for surgical intervention in CP include poorly controlled pain, duodenal, biliary and pancreatic duct obstruction, and suspicion of cancer (184).

Surgery for CP can be broadly classified into three categories: drainage procedures, partial pancreatic resection including or not the duodenum, and total pancreatectomy. Recently, Kamper *et al.* (185), reviewed all the available techniques in detail. In drainage procedures a dilated pancreatic duct is cut open and anastomosed to the proximal jejunum. The most common drainage procedures are the modified Puestow procedure,

also known as lateral pancreatico-jejunostomy, and the Frey procedure, which in addition to a pancreaticojejunostomy includes coring of the pancreatic head. In patients with persistent inflammation of the pancreatic head without upstream ductal dilatation, a resective surgery such as a classic pancreaticoduodenectomy or a duodenum-preserving head resection (Beger procedure) can be performed.

Theoretically, the type of procedure may deeply affect short- and long-term nutritional outcomes, since the extension of the parenchyma resection, as well as the preservation of the duodenum and bile natural transit, and pancreatic secretion may represent key factors for endocrine and exocrine functions (186, 187).

Meta-analyses showed better postoperative pain relief and improved quality of life with the Beger procedure compared with conventional pancreaticoduodenectomy (188, 189). However, the studies included had a high grade of heterogeneity and a recent large prospective large RCT showed no significant difference between procedures in the long-term nutritional status, quality of life, and preservation of the exocrine pancreatic function (190).

A 2015 meta-analysis of 23 studies compared outcomes of the Frey procedure with pancreaticoduodenectomy and the Berger procedure (191). Short-term quality of life and pancreatic function outcomes were more favorable in patients who had the Frey procedure than in those who had pancreaticoduodenectomy. Long-term follow-up data from an RCT comparing the Frey and Berger procedures for CP showed no significant difference in endocrine or exocrine insufficiency more than a decade after surgery (192).

29. What is the risk of developing osteoporosis or osteopenia in patients with CP?

Statement 6

Patients with CP are at risk for osteoporosis (almost one out of four) and at high risk (about two out of three), for osteopathy (either osteoporosis or osteopenia).

Strong consensus (97% agreement)

Commentary

Osteoporosis is characterized by structural deterioration of bone tissue and low bone mass, leading to bone fragility and increased risk of fracture (193). Osteoporosis and osteopenia are defined by the World Health Organization according to T-scores (a T-score between -1.0 and -2.5 standard deviations is defined as osteopenia; a T-score below -2.5 standard deviations is defined as osteoporosis), T-scores compare bone density values with those of young adults (peak bone mass) (194). Osteoporosis and osteopenia can also be defined according to Z-score (Z-score < -1 defined as osteopenia, Z-score < -2 defined as osteoporosis). The Z-scores represents gender- and age-matched controls for the evaluation of secondary osteoporosis, they are usually used in premenopausal women, men under the age of 50, and in children (195).

A systematic review and meta-analysis including ten studies applied the definition in accordance with the T-scores in eight and the Z-scores in two studies. It revealed that, based on the random-effects model of the total 513 patients with CP included, a pooled prevalence rate of osteoporosis of 24.3% (95% CI 16.6 to 32.0%) and osteopathy (either osteoporosis or osteopenia) of 65% (95% CI 54.7 to 74.0%) (196). Two of the included studies revealed osteoporosis rate for controls respectively 8.6 and 10.2%. All the included studies had relatively small sample sizes (< 100) and considerable heterogeneity; therefore, subgroup analyses were not acquiescent. Certain patterns

were, however, evident from the studies included, like an association between pancreatic enzyme insufficiency and lower bone mineral density. On the contrary, the available data failed to show direct associations between serum vitamin D concentrations and low bone mineral density. These data suggest that vitamin D deficiency is not the sole driver of bone demineralization, other factors that may be of importance for premature bone demineralization in CP are heavy smoking, low physical activity, and chronic inflammation (197).

The important clinical endpoint of osteoporosis is bone fracture. Two large retrospective studies shed light on this regarding patients with CP. The first is a cohort database study, examining patients with CP at a single tertiary care center. A total of 3,192 patients with CP and 1,436,699 controls were included in the study. The fracture prevalence (patients with fracture per total patients) was 1.1% in controls (16,208/1,436,699) and 4.8% in patients with CP (154/3192); in comparison Crohn's disease revealed a risk of 3.0% (182/6057); liver cirrhosis 4.8% (805/16,658) and celiac disease 5.0% (74/1480) (198).

The second, a Danish retrospective cohort study including 2594 patients with CP revealed an adjusted hazard ratio for any fracture of 1.7 (95% CI 1.6 to 1.8) (199). Patients with CP receiving PERT for fat malabsorption had a lower risk of fractures than other CP patients (HR 0.8; 95% CI 0.7 to 0.9).

30. What methods should be used to identify patients who are at risk?

Recommendation 41

Dual-energy X-ray absorptiometry (DXA) shall be used to identify patients with CP with osteopathy.

Grade of Recommendation A – Strong consensus (100% agreement)**Commentary**

The American College of Radiology aims to rate the appropriateness of several radiological modalities for specific patient populations. Although they do not mention CP explicitly, they do state that in premenopausal females and males 20 - 50 years of age with malabsorption, DXA of the lumbar spine and hip(s) or distal forearm is usually an appropriate diagnostic modality to identify low bone mineral density (200). It is not yet well defined when and to whom these tests should be offered in patients with CP. However, there are recommendations from the American Gastroenterological Association on the detection of osteoporosis in other gastrointestinal diseases: recommending that patients with at least one additional osteoporosis risk factor should undergo initial screening with DXA (201). This recommendation was specifically for inflammatory bowel disease, celiac disease, and post-gastrectomy patients. The recently published HaPanEU guidelines on CP argued that bone density testing by DXA should be extended to patients with CP with an additional risk; post-menopausal women, those with previous low-trauma fractures, men over 50 years and those with malabsorption (4). They further stated that considering the associated morbidity and cost of bone fractures when prevention is within range (202), a baseline bone density assessment for all patients with CP may be worth considering.

31. What is the recommended management for the prevention and treatment of these conditions?

Recommendation 42

Basic preventive measures should be advised to all patients with CP including adequate calcium/vitamin D intake and, if indicated, pancreatic enzyme supplementation, regular weight-bearing exercise and smoking and alcohol avoidance. Additional pharmacologic treatment should be reserved for patients with osteopathy and, in particular, osteoporosis.

Grade of Recommendation GPP – Strong consensus (97% agreement)

Commentary

The reasons for osteopathy in CP are multifactorial; (i) low serum vitamin D concentrations due to impaired absorption of fat-soluble vitamin D, poor dietary intake (including calcium) and/or sunshine exposure, (ii) smoking and alcohol intake, (iii) low physical activity, and (iv) chronic inflammation, all contribute. Therefore, basic preventive measures should be advised to all patients with CP including adequate calcium/vitamin D intake and PERT if indicated, regular weight-bearing exercise and avoidance of smoking and alcohol (4). Research on pharmaceutical supplementation of vitamin D and calcium in patients with osteopenia and adding bisphosphonates in osteoporosis has mainly been performed in post-menopausal women and elderly patients. Based on these findings, and bearing in mind that the cost and side effects are limited, one could consider in patients with osteopathy to supplement vitamin D (800 IU) and calcium (500 - 1,000 mg) daily (149). In patients with osteopenia it is recommended to repeat the DXA every two years, whereby in patients with osteoporosis there are no specific recommendations beside appropriate medication, screening for other causes and/or referral to a bone specialist (4).

Journal Pre-proof

Conflict of interest

The expert members of the working group were accredited by the ESPEN Guidelines Group, the ESPEN Education and Clinical Practice Committee, and the ESPEN executive. All expert members have declared their individual conflicts of interest according to the rules of the International Committee of Medical Journal Editors (ICMJE). If potential conflicts were indicated, they were reviewed by the ESPEN guideline officers and, in cases of doubts, by the ESPEN executive. None of the expert panel had to be excluded from the working group or from co-authorship because of serious conflicts. The conflict of interest forms are stored at the ESPEN guideline office and can be reviewed by ESPEN members with legitimate interest upon request to the ESPEN executive.

Funding statement

This guideline was solely financed by ESPEN, the European Society for Clinical Nutrition and Metabolism.

Author Contributions

All authors contributed: literature research, PICO questions and writing the corresponding recommendation and comments; MA: overall manuscript writing and editing; DNL and SCB: critical revision of the final manuscript; all authors approved the final submitted version of the manuscript.

Acknowledgement

The authors thank the ESPEN guidelines office for the secretarial work and preparation of the evidence tables.

1180 **Figure legends**

1181 Figure 1: Algorithm suggesting nutritional management in acute pancreatitis. HTG:
1182 hypertriglyceridemia; EN: enteral nutrition; PN: parenteral nutrition. Adapted from
1183 Adiamah et al. (28).

Journal Pre-proof

References

1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut*. 2013;62:102-11.
2. Arvanitakis M, Dumonceau JM, Albert J, Badaoui A, Bali MA, Barthet M, et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. *Endoscopy*. 2018;50:524-46.
3. Trikudanathan G, Wolbrink DRJ, van Santvoort HC, Mallery S, Freeman M, Besselink MG. Current Concepts in Severe Acute and Necrotizing Pancreatitis: An Evidence-Based Approach. *Gastroenterology*. 2019;156:1994-2007 e3.
4. Lohr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). *United European Gastroenterol J*. 2017;5:153-99.
5. Dumonceau JM, Delhay M, Tringali A, Arvanitakis M, Sanchez-Yague A, Vaysse T, et al. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated August 2018. *Endoscopy*. 2019;51:179-93.
6. Bischoff SC, Singer P, Koller M, Barazzoni R, Cederholm T, van Gossum A. Standard operating procedures for ESPEN guidelines and consensus papers. *Clin Nutr*. 2015;34:1043-51.
7. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a guideline developer's handbook. Revised version. Edinburgh: SIGN. 2014.
8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) – Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. 2012.
9. Eckerwall GE, Tingstedt BB, Bergenzaun PE, Andersson RG. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery--a randomized clinical study. *Clin Nutr*. 2007;26:758-63.
10. Wu LM, Sankaran SJ, Plank LD, Windsor JA, Petrov MS. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. *Br J Surg*. 2014;101:1644-56.
11. Roberts KM, Nahikian-Nelms M, Ukleja A, Lara LF. Nutritional Aspects of Acute Pancreatitis. *Gastroenterol Clin North Am*. 2018;47:77-94.
12. Sobral-Oliveira MB, Faintuch J, Guarita DR, Oliveira CP, Carrilho FJ. Nutritional profile of asymptomatic alcoholic patients. *Arq Gastroenterol*. 2011;48:112-8.
13. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc EWG. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr*. 2003;22:321-36.
14. Guerra RS, Fonseca I, Sousa AS, Jesus A, Pichel F, Amaral TF. ESPEN diagnostic criteria for malnutrition - A validation study in hospitalized patients. *Clin Nutr*. 2017;36:1326-32.
15. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr*. 2017;36:49-64.
16. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. *Clin Nutr*. 2018.
17. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American

- Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr.* 2016;40:159-211.
18. Knudsen AW, Naver A, Bisgaard K, Nordgaard-Lassen I, Becker U, Krag A, et al. Nutrition impact symptoms, handgrip strength and nutritional risk in hospitalized patients with gastroenterological and liver diseases. *Scand J Gastroenterol.* 2015;50:1191-8.
 19. Khatua B, El-Kurdi B, Singh VP. Obesity and pancreatitis. *Curr Opin Gastroenterol.* 2017;33:374-82.
 20. Teich N, Aghdassi A, Fischer J, Walz B, Caca K, Wallochny T, et al. Optimal timing of oral refeeding in mild acute pancreatitis: results of an open randomized multicenter trial. *Pancreas.* 2010;39:1088-92.
 21. Zhao XL, Zhu SF, Xue GJ, Li J, Liu YL, Wan MH, et al. Early oral refeeding based on hunger in moderate and severe acute pancreatitis: a prospective controlled, randomized clinical trial. *Nutrition.* 2015;31:171-5.
 22. Li J, Xue GJ, Liu YL, Javed MA, Zhao XL, Wan MH, et al. Early oral refeeding wisdom in patients with mild acute pancreatitis. *Pancreas.* 2013;42:88-91.
 23. Larino-Noia J, Lindkvist B, Iglesias-Garcia J, Seijo-Rios S, Iglesias-Canle J, Dominguez-Munoz JE. Early and/or immediately full caloric diet versus standard refeeding in mild acute pancreatitis: a randomized open-label trial. *Pancreatology.* 2014;14:167-73.
 24. Sathiaraj E, Murthy S, Mansard MJ, Rao GV, Mahukar S, Reddy DN. Clinical trial: oral feeding with a soft diet compared with clear liquid diet as initial meal in mild acute pancreatitis. *Aliment Pharmacol Ther.* 2008;28:777-81.
 25. Moraes JM, Felga GE, Chebli LA, Franco MB, Gomes CA, Gaburri PD, et al. A full solid diet as the initial meal in mild acute pancreatitis is safe and result in a shorter length of hospitalization: results from a prospective, randomized, controlled, double-blind clinical trial. *J Clin Gastroenterol.* 2010;44:517-22.
 26. Horibe M, Nishizawa T, Suzuki H, Minami K, Yahagi N, Iwasaki E, et al. Timing of oral refeeding in acute pancreatitis: A systematic review and meta-analysis. *United European Gastroenterol J.* 2016;4:725-32.
 27. Bevan MG, Asrani VM, Bharmal S, Wu LM, Windsor JA, Petrov MS. Incidence and predictors of oral feeding intolerance in acute pancreatitis: A systematic review, meta-analysis, and meta-regression. *Clin Nutr.* 2017;36:722-9.
 28. Adiamah A, Psaltis E, Crook M, Lobo DN. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. *Clin Nutr.* 2018;37:1810-22.
 29. Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. *Eur J Intern Med.* 2014;25:689-94.
 30. Carr RA, Rejowski BJ, Cote GA, Pitt HA, Zyromski NJ. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? *Pancreatology.* 2016;16:469-76.
 31. Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. *BMJ.* 2004;328:1407.
 32. Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: a meta-analysis of randomized trials. *Arch Surg.* 2008;143:1111-7.
 33. Petrov MS, Pylypchuk RD, Emelyanov NV. Systematic review: nutritional support in acute pancreatitis. *Aliment Pharmacol Ther.* 2008;28:704-12.

34. Cao Y, Xu Y, Lu T, Gao F, Mo Z. Meta-analysis of enteral nutrition versus total parenteral nutrition in patients with severe acute pancreatitis. *Ann Nutr Metab.* 2008;53:268-75.
35. Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA. Enteral versus parenteral nutrition for acute pancreatitis. *Cochrane Database Syst Rev.* 2010:CD002837.
36. Petrov MS, Whelan K. Comparison of complications attributable to enteral and parenteral nutrition in predicted severe acute pancreatitis: a systematic review and meta-analysis. *Br J Nutr.* 2010;103:1287-95.
37. Quan H, Wang X, Guo C. A meta-analysis of enteral nutrition and total parenteral nutrition in patients with acute pancreatitis. *Gastroenterol Res Pract.* 2011;2011:698248.
38. Yi F, Ge L, Zhao J, Lei Y, Zhou F, Chen Z, et al. Meta-analysis: total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. *Intern Med.* 2012;51:523-30.
39. Yao H, He C, Deng L, Liao G. Enteral versus parenteral nutrition in critically ill patients with severe pancreatitis: a meta-analysis. *Eur J Clin Nutr.* 2018;72:66-8.
40. Li W, Liu J, Zhao S, Li J. Safety and efficacy of total parenteral nutrition versus total enteral nutrition for patients with severe acute pancreatitis: a meta-analysis. *J Int Med Res.* 2018;46:3948-58.
41. Wu P, Li L, Sun W. Efficacy comparisons of enteral nutrition and parenteral nutrition in patients with severe acute pancreatitis: a meta-analysis from randomized controlled trials. *Biosci Rep.* 2018;38.
42. Qi D, Yu B, Huang J, Peng M. Meta-Analysis of Early Enteral Nutrition Provided Within 24 Hours of Admission on Clinical Outcomes in Acute Pancreatitis. *JPEN J Parenter Enteral Nutr.* 2018;42:1139-47.
43. Bakker OJ, van Brunschot S, Farre A, Johnson CD, Kalfarentzos F, Louie BE, et al. Timing of enteral nutrition in acute pancreatitis: meta-analysis of individuals using a single-arm of randomised trials. *Pancreatology.* 2014;14:340-6.
44. Li X, Ma F, Jia K. Early enteral nutrition within 24 hours or between 24 and 72 hours for acute pancreatitis: evidence based on 12 RCTs. *Med Sci Monit.* 2014;20:2327-35.
45. Song J, Zhong Y, Lu X, Kang X, Wang Y, Guo W, et al. Enteral nutrition provided within 48 hours after admission in severe acute pancreatitis: A systematic review and meta-analysis. *Medicine (Baltimore).* 2018;97:e11871.
46. Petrov MS, Pylypchuk RD, Uchugina AF. A systematic review on the timing of artificial nutrition in acute pancreatitis. *Br J Nutr.* 2009;101:787-93.
47. Feng P, He C, Liao G, Chen Y. Early enteral nutrition versus delayed enteral nutrition in acute pancreatitis: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore).* 2017;96:e8648.
48. Bakker OJ, van Brunschot S, van Santvoort HC, Besselink MG, Bollen TL, Boermeester MA, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. *N Engl J Med.* 2014;371:1983-93.
49. Stimac D, Poropat G, Hauser G, Licul V, Franjic N, Valkovic Zujic P, et al. Early nasojejunal tube feeding versus nil-by-mouth in acute pancreatitis: A randomized clinical trial. *Pancreatology.* 2016;16:523-8.
50. Jin M, Zhang H, Lu B, Li Y, Wu D, Qian J, et al. The optimal timing of enteral nutrition and its effect on the prognosis of acute pancreatitis: A propensity score matched cohort study. *Pancreatology.* 2017;17:651-7.

51. Tiengou LE, Gloro R, Pouzoulet J, Bouhier K, Read MH, Arnaud-Battandier F, et al. Semi-elemental formula or polymeric formula: is there a better choice for enteral nutrition in acute pancreatitis? Randomized comparative study. *JPEN J Parenter Enteral Nutr.* 2006;30:1-5.
52. Petrov MS, Loveday BP, Pylypchuk RD, McIlroy K, Phillips AR, Windsor JA. Systematic review and meta-analysis of enteral nutrition formulations in acute pancreatitis. *Br J Surg.* 2009;96:1243-52.
53. Poropat G, Giljaca V, Hauser G, Stimac D. Enteral nutrition formulations for acute pancreatitis. *Cochrane Database Syst Rev.* 2015:CD010605.
54. Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *Am J Gastroenterol.* 2005;100:432-9.
55. Kumar A, Singh N, Prakash S, Saraya A, Joshi YK. Early enteral nutrition in severe acute pancreatitis: a prospective randomized controlled trial comparing nasojejunal and nasogastric routes. *J Clin Gastroenterol.* 2006;40:431-4.
56. Singh N, Sharma B, Sharma M, Sachdev V, Bhardwaj P, Mani K, et al. Evaluation of early enteral feeding through nasogastric and nasojejunal tube in severe acute pancreatitis: a noninferiority randomized controlled trial. *Pancreas.* 2012;41:153-9.
57. Petrov MS, Correia MI, Windsor JA. Nasogastric tube feeding in predicted severe acute pancreatitis. A systematic review of the literature to determine safety and tolerance. *JOP.* 2008;9:440-8.
58. Nally DM, Kelly EG, Clarke M, Ridgway P. Nasogastric nutrition is efficacious in severe acute pancreatitis: a systematic review and meta-analysis. *Br J Nutr.* 2014;112:1769-78.
59. Chang YS, Fu HQ, Xiao YM, Liu JC. Nasogastric or nasojejunal feeding in predicted severe acute pancreatitis: a meta-analysis. *Crit Care.* 2013;17:R118.
60. Zhu Y, Yin H, Zhang R, Ye X, Wei J. Nasogastric Nutrition versus Nasojejunal Nutrition in Patients with Severe Acute Pancreatitis: A Meta-Analysis of Randomized Controlled Trials. *Gastroenterol Res Pract.* 2016;2016:6430632.
61. Smit M, Buddingh KT, Bosma B, Nieuwenhuijs VB, Hofker HS, Zijlstra JG. Abdominal Compartment Syndrome and Intra-abdominal Ischemia in Patients with Severe Acute Pancreatitis. *World J Surg.* 2016;40:1454-61.
62. Talukdar R, Bhattacharrya A, Rao B, Sharma M, Nageshwar Reddy D. Clinical utility of the revised Atlanta classification of acute pancreatitis in a prospective cohort: have all loose ends been tied? *Pancreatol.* 2014;14:257-62.
63. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. *N Engl J Med.* 2010;362:1491-502.
64. van Brunschot S, Hollemans RA, Bakker OJ, Besselink MG, Baron TH, Beger HG, et al. Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients. *Gut.* 2018;67:697-706.
65. van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. *Lancet.* 2018;391:51-8.
66. Dua MM, Worhunsky DJ, Malhotra L, Park WG, Poultsides GA, Norton JA, et al. Transgastric pancreatic necrosectomy-expedited return to prepancreatitis health. *J Surg Res.* 2017;219:11-7.

67. Horvath K, Freeny P, Escallon J, Heagerty P, Comstock B, Glickerman DJ, et al. Safety and efficacy of video-assisted retroperitoneal debridement for infected pancreatic collections: a multicenter, prospective, single-arm phase 2 study. *Arch Surg*. 2010;145:817-25.
68. Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. *Intensive Care Med*. 2013;39:1190-206.
69. Bezmarevic M, Mirkovic D, Soldatovic I, Stamenkovic D, Mitrovic N, Perisic N, et al. Correlation between procalcitonin and intra-abdominal pressure and their role in prediction of the severity of acute pancreatitis. *Pancreatology*. 2012;12:337-43.
70. Meier RF, Beglinger C. Nutrition in pancreatic diseases. *Best Pract Res Clin Gastroenterol*. 2006;20:507-29.
71. Dickerson RN, Vehe KL, Mullen JL, Feurer ID. Resting energy expenditure in patients with pancreatitis. *Crit Care Med*. 1991;19:484-90.
72. van Brunschot S, Schut AJ, Bouwense SA, Besselink MG, Bakker OJ, van Goor H, et al. Abdominal compartment syndrome in acute pancreatitis: a systematic review. *Pancreas*. 2014;43:665-74.
73. Marvin RG, McKinley BA, McQuiggan M, Cocanour CS, Moore FA. Nonocclusive bowel necrosis occurring in critically ill trauma patients receiving enteral nutrition manifests no reliable clinical signs for early detection. *Am J Surg*. 2000;179:7-12.
74. Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MP, Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. *Intensive Care Med*. 2017;43:380-98.
75. Marcos-Neira P, Zubia-Olaskoaga F, Lopez-Cuenca S, Bordeje-Laguna L, Epidemiology of Acute Pancreatitis in Intensive Care Medicine study g. Relationship between intra-abdominal hypertension, outcome and the revised Atlanta and determinant-based classifications in acute pancreatitis. *BJS Open*. 2017;1:175-81.
76. Sun JK, Li WQ, Ke L, Tong ZH, Ni HB, Li G, et al. Early enteral nutrition prevents intra-abdominal hypertension and reduces the severity of severe acute pancreatitis compared with delayed enteral nutrition: a prospective pilot study. *World J Surg*. 2013;37:2053-60.
77. Reintam Blaser A, Malbrain M, Regli A. Abdominal pressure and gastrointestinal function: an inseparable couple? *Anaesthesiology intensive therapy*. 2017;49:146-58.
78. Tsuei BJ, Magnuson B, Swintosky M, Flynn J, Boulanger BR, Ochoa JB, et al. Enteral nutrition in patients with an open peritoneal cavity. *Nutr Clin Pract*. 2003;18:253-8.
79. Cothren CC, Moore EE, Ciesla DJ, Johnson JL, Moore JB, Haenel JB, et al. Postinjury abdominal compartment syndrome does not preclude early enteral feeding after definitive closure. *Am J Surg*. 2004;188:653-8.
80. Byrnes MC, Reicks P, Irwin E. Early enteral nutrition can be successfully implemented in trauma patients with an "open abdomen". *Am J Surg*. 2010;199:359-62; discussion 63.
81. Burlew CC, Moore EE, Cuschieri J, Jurkovich GJ, Codner P, Nirula R, et al. Who should we feed? Western Trauma Association multi-institutional study of enteral nutrition in the open abdomen after injury. *J Trauma Acute Care Surg*. 2012;73:1380-7; discussion 7-8.
82. Collier B, Guillaumondegui O, Cotton B, Donahue R, Conrad A, Groh K, et al. Feeding the open abdomen. *JPEN J Parenter Enteral Nutr*. 2007;31:410-5.

83. Dissanaike S, Pham T, Shalhub S, Warner K, Hennessy L, Moore EE, et al. Effect of immediate enteral feeding on trauma patients with an open abdomen: protection from nosocomial infections. *J Am Coll Surg*. 2008;207:690-7.
84. Jeurnink SM, Nijs MM, Prins HA, Greving JP, Siersema PD. Antioxidants as a treatment for acute pancreatitis: A meta-analysis. *Pancreatology*. 2015;15:203-8.
85. Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, et al. Pharmacological interventions for acute pancreatitis. *Cochrane Database Syst Rev*. 2017;4:CD011384.
86. Asrani V, Chang WK, Dong Z, Hardy G, Windsor JA, Petrov MS. Glutamine supplementation in acute pancreatitis: a meta-analysis of randomized controlled trials. *Pancreatology*. 2013;13:468-74.
87. Yong L, Lu QP, Liu SH, Fan H. Efficacy of Glutamine-Enriched Nutrition Support for Patients With Severe Acute Pancreatitis: A Meta-Analysis. *JPEN J Parenter Enteral Nutr*. 2016;40:83-94.
88. Jafari T, Feizi A, Askari G, Fallah AA. Parenteral immunonutrition in patients with acute pancreatitis: a systematic review and meta-analysis. *Clin Nutr*. 2015;34:35-43.
89. Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. *Crit Care*. 2014;18:R57.
90. Besselink MG, van Santvoort HC, van der Heijden GJ, Buskens E, Gooszen HG, Dutch Acute Pancreatitis Study G. New randomized trial of probiotics in pancreatitis needed? Caution advised. *Langenbecks Arch Surg*. 2009;394:191-2; author reply 3-4.
91. Kahl S, Schutte K, Glasbrenner B, Mayerle J, Simon P, Henniges F, et al. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study. *JOP*. 2014;15:165-74.
92. Patankar RV, Chand R, Johnson CD. Pancreatic enzyme supplementation in acute pancreatitis. *HPB Surg*. 1995;8:159-62.
93. Fernandez M, Arvanitakis M, Musala C, Deviere J, Van Steenberghe W, Putzeys V, et al. The Belgian national registry on chronic pancreatitis: A prospective multi-centre study covering more than 800 patients in one year. *Pancreatology*. 2017;17:572-9.
94. Hao L, Wang LS, Liu Y, Wang T, Guo HL, Pan J, et al. The different course of alcoholic and idiopathic chronic pancreatitis: A long-term study of 2,037 patients. *PLoS One*. 2018;13:e0198365.
95. Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. *World J Gastroenterol*. 2013;19:7276-81.
96. Meier R, Ockenga J, Pertkiewicz M, Pap A, Milinic N, Macfie J, et al. ESPEN Guidelines on Enteral Nutrition: Pancreas. *Clin Nutr*. 2006;25:275-84.
97. Gianotti L, Meier R, Lobo DN, Bassi C, Dejong CH, Ockenga J, et al. ESPEN Guidelines on Parenteral Nutrition: pancreas. *Clin Nutr*. 2009;28:428-35.
98. Min M, Patel B, Han S, Bocelli L, Kheder J, Vaze A, et al. Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences. *Pancreas*. 2018;47:1015-8.
99. Olesen SS, Frandsen LK, Poulsen JL, Vestergaard P, Rasmussen HH, Drewes AM. The prevalence of underweight is increased in chronic pancreatitis outpatients and associates with reduced life quality. *Nutrition*. 2017;43-44:1-7.
100. Duggan SN, Smyth ND, O'Sullivan M, Feehan S, Ridgway PF, Conlon KC. The prevalence of malnutrition and fat-soluble vitamin deficiencies in chronic pancreatitis. *Nutr Clin Pract*. 2014;29:348-54.

101. Wehler M, Nichterlein R, Fischer B, Farnbacher M, Reulbach U, Hahn EG, et al. Factors associated with health-related quality of life in chronic pancreatitis. *Am J Gastroenterol.* 2004;99:138-46.
102. Olesen SS, Buyukuslu A, Kohler M, Rasmussen HH, Drewes AM. Sarcopenia associates with increased hospitalization rates and reduced survival in patients with chronic pancreatitis. *Pancreatology.* 2019.
103. Sikkens EC, Cahen DL, Koch AD, Braat H, Poley JW, Kuipers EJ, et al. The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. *Pancreatology.* 2013;13:238-42.
104. Sikkens EC, Cahen DL, van Eijck C, Kuipers EJ, Bruno MJ. Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a Dutch national survey. *Pancreatology.* 2012;12:71-3.
105. Hebuterne X, Hastier P, Peroux JL, Zeboudj N, Delmont JP, Rampal P. Resting energy expenditure in patients with alcoholic chronic pancreatitis. *Dig Dis Sci.* 1996;41:533-9.
106. Lindkvist B, Phillips ME, Dominguez-Munoz JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use. *Pancreatology.* 2015;15:589-97.
107. Dominguez-Munoz JE, Phillips M. Nutritional Therapy in Chronic Pancreatitis. *Gastroenterol Clin North Am.* 2018;47:95-106.
108. Weimann A, Braga M, Harsanyi L, Laviano A, Ljungqvist O, Soeters P, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. *Clin Nutr.* 2006;25:224-44.
109. Sanford DE, Sanford AM, Fields RC, Hawkins WG, Strasberg SM, Linehan DC. Severe nutritional risk predicts decreased long-term survival in geriatric patients undergoing pancreaticoduodenectomy for benign disease. *J Am Coll Surg.* 2014;219:1149-56.
110. Schnelldorfer T, Adams DB. The effect of malnutrition on morbidity after Surgery for chronic pancreatitis. *Am Surg.* 2005;71:466-72; discussion 72-3.
111. Singh S, Midha S, Singh N, Joshi YK, Garg PK. Dietary counseling versus dietary supplements for malnutrition in chronic pancreatitis: a randomized controlled trial. *Clin Gastroenterol Hepatol.* 2008;6:353-9.
112. Dutta SK, Bustin MP, Russell RM, Costa BS. Deficiency of fat-soluble vitamins in treated patients with pancreatic insufficiency. *Ann Intern Med.* 1982;97:549-52.
113. Cheshire J, Kolli S. Vitamin A deficiency due to chronic malabsorption: an ophthalmic manifestation of a systemic condition. *BMJ Case Rep.* 2017;2017.
114. Livingstone C, Davis J, Marvin V, Morton K. Vitamin A deficiency presenting as night blindness during pregnancy. *Ann Clin Biochem.* 2003;40:292-4.
115. Sikkens EC, Cahen DL, van Eijck C, Kuipers EJ, Bruno MJ. The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: a northern European survey: enzyme replacement after surgery. *J Gastrointest Surg.* 2012;16:1487-92.
116. de-Madaria E, Abad-Gonzalez A, Aparicio JR, Aparisi L, Boadas J, Boix E, et al. The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). *Pancreatology.* 2013;13:18-28.
117. Delhaye M, Van Steenberghe W, Cesmeli E, Pelckmans P, Putzeys V, Roeyen G, et al. Belgian consensus on chronic pancreatitis in adults and children: statements on diagnosis and nutritional, medical, and surgical treatment. *Acta Gastroenterol Belg.* 2014;77:47-65.

118. Frulloni L, Falconi M, Gabbrielli A, Gaia E, Graziani R, Pezzilli R, et al. Italian consensus guidelines for chronic pancreatitis. *Dig Liver Dis.* 2010;42 Suppl 6:S381-406.
119. Mirtallo JM, Forbes A, McClave SA, Jensen GL, Waitzberg DL, Davies AR, et al. International consensus guidelines for nutrition therapy in pancreatitis. *JPEN J Parenter Enteral Nutr.* 2012;36:284-91.
120. Maruki J, Sai JK, Watanabe S. Efficacy of low-fat diet against dyspepsia associated with nonalcoholic mild pancreatic disease diagnosed using the Rosemont criteria. *Pancreas.* 2013;42:49-52.
121. Castineira-Alvarino M, Lindkvist B, Luaces-Regueira M, Iglesias-Garcia J, Larino-Noia J, Nieto-Garcia L, et al. The role of high fat diet in the development of complications of chronic pancreatitis. *Clin Nutr.* 2013;32:830-6.
122. Dutta SK, Hlasko J. Dietary fiber in pancreatic disease: effect of high fiber diet on fat malabsorption in pancreatic insufficiency and in vitro study of the interaction of dietary fiber with pancreatic enzymes. *Am J Clin Nutr.* 1985;41:517-25.
123. Caliri S, Benini L, Sembenini C, Gregori B, Carnielli V, Vantini I. Medium-chain triglyceride absorption in patients with pancreatic insufficiency. *Scand J Gastroenterol.* 1996;31:90-4.
124. Caliri S, Benini L, Bonfante F, Brentegani MT, Fioretta A, Vantini I. Pancreatic extracts are necessary for the absorption of elemental and polymeric enteral diets in severe pancreatic insufficiency. *Scand J Gastroenterol.* 1993;28:749-52.
125. Greer JB, Greer P, Sandhu BS, Alkaade S, Wilcox CM, Anderson MA, et al. Nutrition and Inflammatory Biomarkers in Chronic Pancreatitis Patients. *Nutr Clin Pract.* 2018.
126. Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. *Anticancer Res.* 2012;32:1991-8.
127. Lindkvist B, Dominguez-Munoz JE, Luaces-Regueira M, Castineiras-Alvarino M, Nieto-Garcia L, Iglesias-Garcia J. Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis. *Pancreatol.* 2012;12:305-10.
128. Stanga Z, Giger U, Marx A, DeLegge MH. Effect of jejunal long-term feeding in chronic pancreatitis. *JPEN J Parenter Enteral Nutr.* 2005;29:12-20.
129. Skipworth JR, Raptis DA, Wijesuriya S, Puthuchery Z, Olde Damink SW, Imber C, et al. The use of nasojejunal nutrition in patients with chronic pancreatitis. *JOP.* 2011;12:574-80.
130. Ridditid W, Lehman GA, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Short- and long-term outcomes from percutaneous endoscopic gastrostomy with jejunal extension. *Surg Endosc.* 2017;31:2901-9.
131. O'Keefe S, Rolniak S, Raina A, Graham T, Hegazi R, Centa-Wagner P. Enteral feeding patients with gastric outlet obstruction. *Nutr Clin Pract.* 2012;27:76-81.
132. Silk DB. Formulation of enteral diets for use in jejunal enteral feeding. *Proc Nutr Soc.* 2008;67:270-2.
133. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. *Nutr Clin Pract.* 2011;26:349-51.
134. Duggan SN, Ni Chonchubhair HM, Lawal O, O'Connor DB, Conlon KC. Chronic pancreatitis: A diagnostic dilemma. *World J Gastroenterol.* 2016;22:2304-13.
135. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. *Clin Exp Gastroenterol.* 2011;4:55-73.
136. de la Iglesia-Garcia D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. *Gut.* 2017;66:1354-5.

137. Dumasy V, Delhay M, Cotton F, Deviere J. Fat malabsorption screening in chronic pancreatitis. *Am J Gastroenterol*. 2004;99:1350-4.
138. Eddes EH, Masclee AA, Gielkens HA, Verkijk M, Vecht J, Biemond I, et al. Cholecystokinin secretion in patients with chronic pancreatitis and after different types of pancreatic surgery. *Pancreas*. 1999;19:119-25.
139. Marra-Lopez Valenciano C, Bolado Concejo F, Marin Serrano E, Millastre Bocos J, Martinez-Moneo E, Perez Rodriguez E, et al. Prevalence of exocrine pancreatic insufficiency in patients with chronic pancreatitis without follow-up. *PANCR-EVOL Study. Gastroenterol Hepatol*. 2018;41:77-86.
140. Nikfarjam M, Wilson JS, Smith RC, Australasian Pancreatic Club Pancreatic Enzyme Replacement Therapy Guidelines Working G. Diagnosis and management of pancreatic exocrine insufficiency. *Med J Aust*. 2017;207:161-5.
141. Olesen SS, Poulsen JL, Drewes AM, Frokjaer JB, Laukkarinen J, Parhiala M, et al. The Scandinavian baltic pancreatic club (SBPC) database: design, rationale and characterisation of the study cohort. *Scand J Gastroenterol*. 2017;52:909-15.
142. Talley NJ, Holtmann G, Nguyen QN, Gibson P, Bampton P, Veysey M, et al. Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. *J Gastroenterol Hepatol*. 2017;32:1813-7.
143. Szucs A, Marjai T, Szentesi A, Farkas N, Parniczky A, Nagy G, et al. Chronic pancreatitis: Multicentre prospective data collection and analysis by the Hungarian Pancreatic Study Group. *PLoS One*. 2017;12:e0171420.
144. Capurso G, Archibugi L, Pasquali P, Aceti A, Balducci P, Bianchi P, et al. Prevalence of chronic pancreatitis: Results of a primary care physician-based population study. *Dig Liver Dis*. 2017;49:535-9.
145. Campbell JA, Sanders DS, Francis KA, Kurien M, Lee S, Taha H, et al. Should we Investigate Gastroenterology Patients for Pancreatic Exocrine Insufficiency? A Dual Centre UK Study. *J Gastrointest Liver Dis*. 2016;25:303-9.
146. Dominguez-Munoz JE, Lucendo A, Carballo LF, Iglesias-Garcia J, Tenias JM. A Spanish multicenter study to estimate the prevalence and incidence of chronic pancreatitis and its complications. *Rev Esp Enferm Dig*. 2014;106:239-45.
147. Tran TC, van Lanschot JJ, Bruno MJ, van Eijck CH. Functional changes after pancreatoduodenectomy: diagnosis and treatment. *Pancreatol*. 2009;9:729-37.
148. Dominguez-Munoz JE, Iglesias-Garcia J. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy? *JOP*. 2010;11:158-62.
149. Duggan S, O'Sullivan M, Feehan S, Ridgway P, Conlon K. Nutrition treatment of deficiency and malnutrition in chronic pancreatitis: a review. *Nutr Clin Pract*. 2010;25:362-70.
150. Gooden HM, White KJ. Pancreatic cancer and supportive care--pancreatic exocrine insufficiency negatively impacts on quality of life. *Support Care Cancer*. 2013;21:1835-41.
151. Bachmann K, Tomkoetter L, Kutup A, Erbes J, Vashist Y, Mann O, et al. Is the Whipple procedure harmful for long-term outcome in treatment of chronic pancreatitis? 15-years follow-up comparing the outcome after pylorus-preserving pancreatoduodenectomy and Frey procedure in chronic pancreatitis. *Ann Surg*. 2013;258:815-20; discussion 20-1.

152. Regan PT, Malagelada JR, DiMagno EP, Glanzman SL, Go VL. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. *N Engl J Med.* 1977;297:854-8.
153. Layer P, von der Ohe MR, Holst JJ, Jansen JB, Grandt D, Holtmann G, et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. *Gastroenterology.* 1997;112:1624-34.
154. Wooldridge JL, Heubi JE, Amaro-Galvez R, Boas SR, Blake KV, Nasr SZ, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. *J Cyst Fibros.* 2009;8:405-17.
155. Haaber AB, Rosenfalck AM, Hansen B, Hilsted J, Larsen S. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. *Int J Pancreatol.* 2000;27:21-7.
156. Kalvaria I, Labadarios D, Shephard GS, Visser L, Marks IN. Biochemical vitamin E deficiency in chronic pancreatitis. *Int J Pancreatol.* 1986;1:119-28.
157. Mann ST, Stracke H, Lange U, Klor HU, Teichmann J. Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. *Metabolism.* 2003;52:579-85.
158. Haas S, Krins S, Knauerhase A, Lohr M. Altered bone metabolism and bone density in patients with chronic pancreatitis and pancreatic exocrine insufficiency. *JOP.* 2015;16:58-62.
159. Yao ZM, Vance DE. Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. *Biochem Cell Biol.* 1990;68:552-8.
160. Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values. *Aliment Pharmacol Ther.* 1996;10:771-5.
161. Lohr JM, Hummel FM, Pirilis KT, Steinkamp G, Korner A, Henniges F. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. *Eur J Gastroenterol Hepatol.* 2009;21:1024-31.
162. DiMagno EP, Malagelada JR, Go VL, Moertel CG. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. *N Engl J Med.* 1977;296:1318-22.
163. D'Haese JG, Ceyhan GO, Demir IE, Layer P, Uhl W, Lohr M, et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. *Pancreas.* 2014;43:834-41.
164. Ramesh H, Reddy N, Bhatia S, Rajkumar JS, Bapaye A, Kini D, et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. *Pancreatol.* 2013;13:133-9.
165. Thorat V, Reddy N, Bhatia S, Bapaye A, Rajkumar JS, Kini DD, et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study. *Aliment Pharmacol Ther.* 2012;36:426-36.
166. Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. *Am J Gastroenterol.* 2010;105:2276-86.

- 1665 167. Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people
1666 with cystic fibrosis. *Cochrane Database Syst Rev*. 2014;CD008227.
- 1667 168. Bruno MJ, Borm JJ, Hoek FJ, Delzenne B, Hofmann AF, de Goeij JJ, et al. Gastric
1668 transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin
1669 microsphere preparation in patients with chronic pancreatitis. *Dig Dis Sci*. 1998;43:203-
1670 13.
- 1671 169. Taylor CJ, Thieroff-Ekerdt R, Shiff S, Magnus L, Fleming R, Gommoll C.
1672 Comparison of two pancreatic enzyme products for exocrine insufficiency in patients
1673 with cystic fibrosis. *J Cyst Fibros*. 2016;15:675-80.
- 1674 170. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua
1675 M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic
1676 enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized,
1677 three-way crossover study. *Aliment Pharmacol Ther*. 2005;21:993-1000.
- 1678 171. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and
1679 disease. *Gut*. 2005;54 Suppl 6:vi1-28.
- 1680 172. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral
1681 pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-
1682 controlled, parallel group trial in subjects with chronic pancreatitis. *Pancreas*.
1683 2006;33:156-62.
- 1684 173. O'Keefe SJ, Cariem AK, Levy M. The exacerbation of pancreatic endocrine
1685 dysfunction by potent pancreatic exocrine supplements in patients with chronic
1686 pancreatitis. *J Clin Gastroenterol*. 2001;32:319-23.
- 1687 174. Halm U, Loser C, Lohr M, Katschinski M, Mossner J. A double-blind, randomized,
1688 multicentre, crossover study to prove equivalence of pancreatin minimicrospheres
1689 versus microspheres in exocrine pancreatic insufficiency. *Aliment Pharmacol Ther*.
1690 1999;13:951-7.
- 1691 175. Opekun AR, Jr., Sutton FM, Jr., Graham DY. Lack of dose-response with Pancrease
1692 MT for the treatment of exocrine pancreatic insufficiency in adults. *Aliment Pharmacol*
1693 *Ther*. 1997;11:981-6.
- 1694 176. Vecht J, Symersky T, Lamers CB, Masclee AA. Efficacy of lower than standard
1695 doses of pancreatic enzyme supplementation therapy during acid inhibition in patients
1696 with pancreatic exocrine insufficiency. *J Clin Gastroenterol*. 2006;40:721-5.
- 1697 177. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR,
1698 et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children
1699 with cystic fibrosis. *N Engl J Med*. 1997;336:1283-9.
- 1700 178. Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-
1701 Struckmeier S, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release
1702 capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic
1703 pancreatitis or pancreatic surgery. *Aliment Pharmacol Ther*. 2011;33:1152-61.
- 1704 179. Phillips ME. Pancreatic exocrine insufficiency following pancreatic resection.
1705 *Pancreatol*. 2015;15:449-55.
- 1706 180. Dominguez-Munoz JE, Iglesias-Garcia J, Vilarino-Insua M, Iglesias-Rey M. 13C-
1707 mixed triglyceride breath test to assess oral enzyme substitution therapy in patients
1708 with chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2007;5:484-8.
- 1709 181. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Vilarino-Insua M.
1710 Optimising the therapy of exocrine pancreatic insufficiency by the association of a
1711 proton pump inhibitor to enteric coated pancreatic extracts. *Gut*. 2006;55:1056-7.
- 1712 182. Sander-Struckmeier S, Beckmann K, Janssen-van Solingen G, Pollack P.
1713 Retrospective analysis to investigate the effect of concomitant use of gastric acid-

- suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON(R)) in patients with pancreatic exocrine insufficiency. *Pancreas*. 2013;42:983-9.
183. Ni Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). *Pancreatology*. 2018;18:379-85.
184. Majumder S, Chari ST. Chronic pancreatitis. *Lancet*. 2016;387:1957-66.
185. Kemper M, Izbicki JR, Bachmann K. Surgical Treatment of Chronic Pancreatitis: The State of the Art. *Chirurgia (Bucur)*. 2018;113:300-6.
186. Sabater L, Ausania F, Bakker OJ, Boadas J, Dominguez-Munoz JE, Falconi M, et al. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. *Ann Surg*. 2016;264:949-58.
187. Gianotti L, Besselink MG, Sandini M, Hackert T, Conlon K, Gerritsen A, et al. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). *Surgery*. 2018;164:1035-48.
188. Diener MK, Rahbari NN, Fischer L, Antes G, Buchler MW, Seiler CM. Duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for surgical treatment of chronic pancreatitis: a systematic review and meta-analysis. *Ann Surg*. 2008;247:950-61.
189. Yin Z, Sun J, Yin D, Wang J. Surgical treatment strategies in chronic pancreatitis: a meta-analysis. *Arch Surg*. 2012;147:961-8.
190. Diener MK, Huttner FJ, Kieser M, Knebel P, Dorr-Harim C, Distler M, et al. Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. *Lancet*. 2017;390:1027-37.
191. Zhou Y, Shi B, Wu L, Wu X, Li Y. Frey procedure for chronic pancreatitis: Evidence-based assessment of short- and long-term results in comparison to pancreatoduodenectomy and Beger procedure: A meta-analysis. *Pancreatology*. 2015;15:372-9.
192. Bachmann K, Tomkoetter L, Erbes J, Hofmann B, Reeh M, Perez D, et al. Beger and Frey procedures for treatment of chronic pancreatitis: comparison of outcomes at 16-year follow-up. *J Am Coll Surg*. 2014;219:208-16.
193. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. *The American journal of medicine*. 1993;94:646-50.
194. Kanis JA. An update on the diagnosis of osteoporosis. *Curr Rheumatol Rep*. 2000;2:62-6.
195. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, et al. Official positions of the international society for clinical densitometry. *J Clin Endocrinol Metab*. 2004;89:3651-5.
196. Duggan SN, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2014;12:219-28.
197. Uc A, Andersen DK, Bellin MD, Bruce JI, Drewes AM, Engelhardt JF, et al. Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. *Pancreas*. 2016;45:1365-75.
198. Tignor AS, Wu BU, Whitlock TL, Lopez R, Repas K, Banks PA, et al. High prevalence of low-trauma fracture in chronic pancreatitis. *Am J Gastroenterol*. 2010;105:2680-6.

- 1762 199. Bang UC, Benfield T, Bendtsen F, Hyldstrup L, Beck Jensen JE. The risk of fractures
1763 among patients with cirrhosis or chronic pancreatitis. Clin Gastroenterol Hepatol.
1764 2014;12:320-6.
- 1765 200. Expert Panel on Musculoskeletal I, Ward RJ, Roberts CC, Bencardino JT, Arnold E,
1766 Baccei SJ, et al. ACR Appropriateness Criteria((R)) Osteoporosis and Bone Mineral
1767 Density. J Am Coll Radiol. 2017;14:S189-S202.
- 1768 201. American Gastroenterological Association medical position statement: guidelines
1769 on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791-4.
- 1770 202. Prevention and management of osteoporosis. World Health Organization
1771 technical report series. 2003;921:1-164, back cover.
- 1772

Table 1. Levels of evidence

1++	High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1-	Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++	High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2+	Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2-	Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3	Non-analytic studies, e.g. case reports, case series
4	Expert opinion

According to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Source: SIGN 50: A guideline developer's handbook. Quick reference guide October 2014 [SIGN 50]. RCT=randomized controlled trial

Table 2. Grades of recommendation (6)

A	At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B	A body of evidence including studies rated as 2++, directly applicable to the target population; or A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
0	Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2++ or 2+
GPP	Good practice points/expert consensus: Recommended best practice based on the clinical experience of the guideline development group

RCT=randomized controlled trial

Table 3. Classification of the strength of consensus

Strong consensus	Agreement of >90% of the participants
Consensus	Agreement of >75-90% of the participants
Majority agreement	Agreement of 50-75 % of the participants
No consensus	Agreement of <50% of the participants

According to the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Association of the Scientific Medical Societies in Germany) methodology (8)

Table 4. Criteria for systematic search for literature – databases, filters and keywords

Publication date	From 1977 to December 2018
Language	English
Databases	Pubmed, EMBASE, Cochrane library
Filters	human
Publication type	Cohort study, controlled trial, systematic review
Keywords	Acute pancreatitis, chronic pancreatitis, nutrition

Table 5: Nutritional assessment in the patient with chronic pancreatitis

Anthropometric assessment	Biochemical assessment	Symptom assessment	Body composition
<ul style="list-style-type: none"> • Change in body weight • Functional assessment: Hand-grip strength dynamometry / 6-minute walk tests / sit to stand tests. • Skin fold thickness, waist circumference and mid arm muscle circumference. • Presence of ascites / edema 	<ul style="list-style-type: none"> • Fat soluble vitamins (A, D, E, K) • Bone health (Parathyroid hormone) • Trace elements (magnesium, selenium, zinc) • Anemia screen (iron studies, B12, folate, ferritin and CRP) • Glycemic control: HbA1c and random glucose 	<ul style="list-style-type: none"> • Change in dietary intake • Appetite • Presence of symptoms that impact on oral intake (nausea / pain / indigestion / early satiety) • Presence of exocrine / endocrine dysfunction 	<ul style="list-style-type: none"> • CT / US imaging of muscle stores (muscle mass) • DXA scanning (bone mineral density)

CRP = C-reactive protein, HbA1c = hemoglobin A1c, CT = computed tomography, US = ultrasound, DXA = dual-energy X-ray absorptiometry

